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CHAPTER 1: GENERAL INTRODUCTION 
 
 
Introduction 
 
Leishmaniasis is a group of vector-borne diseases caused by obligate intracellular 
protozoan parasites of the genus Leishmania. Leishmania transmission primarily occurs via 
the bite of infected female sandflies, which inoculate Leishmania promastigotes into 
mammalian hosts. Promastigotes are internalized by phagocytic cells of the immune system, 
primarily macrophages and dendritic cells (DC), and begin the differentiation process into 
amastigotes, the parasite form which persists in the host. Disease outcome is dependent on 
both the host’s immune status and the species of parasite. Clinical manifestation can range 
from self-healing cutaneous lesions to fatal disseminated visceral disease. Leishmaniasis is 
endemic in 88 countries affecting regions in the tropics and subtropics, with an estimated 
350 million people are at risk for infection and disease and of the 1.5-2 million new cases 
each year, 70,000 of which are fatal.  
To date no effective vaccine against Leishmania for humans is available and 
although a variety of drugs are available to treat leishmaniasis, treatment efficacy remains 
subpar. In most cases parasites are never completely eliminated and disease 
recrudescence is very common. Additionally, the emergence of parasite resistance, 
increasing co-infections—especially with the increasing incidence of HIV—and the high cost 
of treatment  all decrease the number of treatment options available and the chances of 
effective cure.  Novel therapeutic options for leishmaniasis are in dire need.  
In cases of visceral leishmaniasis, early detection is key if successful therapeutic 
treatment is to be achieved. In endemic areas, canine infection with Leishmania infantum is 
considered the most important risk factor for human infection. Recently, canine visceral 
leishmaniasis, caused by Leishmania infantum, has been reported in the United States. 
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Disease manifestation and progression in L. infantum-infected Foxhounds in the U.S. 
parallels visceral leishmaniasis in naturally- and experimentally-infected animals as well as 
humans. This makes the Foxhounds an attractive model to study natural L. infantum 
infection and visceral leishmaniasis disease progression. The objective of the first study of 
the dissertation is to characterize the temporal humoral and cellular immune responses to 
natural L. infantum infection in Foxhounds. The goals are to determine the immune 
parameters that characterize the different clinical stages of disease in infected animals: (1) 
CD4+ lymphoproliferative responses, (2) cytokine production profile, and (3) antibody 
responses. The information obtained from these studies describes for the first time the 
temporal immune response to L. infantum in naturally-infected Foxhounds in the US in the 
absence of vector transmission. In addition, this work identifies immune parameters that can 
prognosticate visceral leishmaniasis disease progression.  
 Current treatment options, based solely on chemotherapy, are not always effective. 
Novel treatment options that target the parasite and work with the host immune response 
should be considered. The murine model of cutaneous leishmaniasis using L. amazonensis 
infection provides an excellent model to study host-parasite interactions that may lead to a 
non-productive immune response. Understanding these interactions may allow us to 
develop therapeutic strategies that directly enhance the host immune response against 
Leishmania. Dendritic cells play a critical role as inducers of adaptive immune responses 
and serve as host cells for Leishmania parasites. The goals of the second study of the 
dissertation are to understand the mechanism of DC modulation following L. amazonensis 
infection. More specifically, this work will determine (1) the maturation phenotype of infected 
DC in vivo and in vitro, and (2) will explore changes in MAP kinase ERK activation and its 
role in DC maturation.  
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The objective of the third study in this dissertation will characterize the endosomal 
mechanism of L. amazonensis-mediated ERK activation. In the previous chapter we show 
that following infection with L. amazonensis promastigotes, ERK1/2 activation is delayed for 
several hours, at which time most parasites are found intracellularly within infected cells. 
Modulation of signaling pathways by Leishmania parasites has been previously described. 
However, little is known regarding the mechanisms employed by Leishmania parasites to 
modulate host cell signaling from the parasitophorous vacuole—the intracellular, membrane-
bound compartment in which they reside inside the host cell. The work in this section will 
determine (1) whether live parasites are required to trigger ERK1/2 activation from infected 
DC, (2) characterize the endosomal compartment in which L. amazonensis parasites are 
found during the time of ERK1/2 activation, and (3) determine if ERK1/2-specific scaffold 
proteins associate with L. amazonensis-containing organelles.  The information obtained 
from the first set of studies furthers our understanding of host-parasite amastigote-specific 
interactions and provides evidence for the use of ERK inhibitors as immunomodulators to 
directly enhance the host immune response after Leishmania infection. The second set of 
studies characterizes a L. amazonensis-mediated, scaffold-specific mechanism of ERK1/2 
activation. The information from this work bring forth the possibility of developing treatment 
options that specifically modulate pathogenic ERK1/2 phosphorylation, sparing more 
universal functions. These therapeutic treatments could serve to treat not only L. 
amazonensis infection, but other diseases where aberrant activation of ERK1/2 leads to 
disease.  
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LITERATURE REVIEW 
 
Leishmaniasis 
 
Epidemiology and Ecology 
 
Leishmaniasis is a group of vector-borne diseases caused by obligate intracellular 
protozoan parasites of the genus Leishmania. Twenty one different species of Leishmania 
have been characterized as disease-causing agents (20). Disease outcome is dependent on 
both the host’s immune status and the infecting parasite species. Clinical manifestation 
ranges from self-healing cutaneous lesions to fatal visceral disease. Leishmaniasis is 
endemic in 88 countries affecting regions in the tropics and subtropics, and a variety of 
settings including rain forests, deserts, rural and peri-urban areas (54).  Currently, an 
estimated 350 million people are at risk for infection and disease and of the 1.5-2 million 
new cases each year, 70,000 are fatal (111).  
Leishmania transmission primarily occurs via the bite of infected female sandflies 
belonging to one of two genuses: Phlebotomous (Old World) and Lutzomyia (New World). 
There are approximately 600 known species of sandflies, but of these only 30 are 
competent vectors (130). Sandflies are found in tropical and sub-tropical climates and live in 
desert or semi-arid regions. In the Old World (Europe, North Africa, Middle East, and Asia) 
sandfly contact with humans results from insect breeding in peridomestic areas, while in the 
New World (the Americas), sandfly contact is associated with humans living or working near 
forests (130). Female sandflies require blood to obtain the necessary proteins for egg 
development. Feeding occurs mostly at dawn and dusk and on a variety of animals including 
mammals, birds and reptiles.  
Classically, Leishmania parasites have a dimorphic life cycle alternating between the 
vector and the mammalian host (Figure 1). Infected sandflies can inoculate a host during a 
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blood meal. The predominant form of the parasite within the vector is the extracellular, 
highly motile, flagellated promastigote. Promastigotes are long and slender (15-30μm by 2-
3μm), covered in a thick glycocalyx composed of a variety of extensively-branched, 
glycosylphosphatidylinositol (GPI)-anchored glyco-conjugates, including lipophosphoglycan 
(LPG) and the metaloprotease glycoprotein (gp) 63 (34). Once introduced into a host, 
promastigotes are internalized by phagocytic cells of the immune system, including 
macrophages, dendritic cells and neutrophils (119).  Following phagocytosis, promastigotes 
are contained within membrane-bound compartments that mature from early phagosomes to 
late phagosomes. Ultimately these late phagosomes will fuse with lysosomes to become 
phagolysosomes. These parasite-containing organelles are referred to as parasitophorous 
vacuoles (PV) (71). Once inside host cells, promastigotes begin differentiating into the 
intracellular form of the parasite, the amastigote. This process takes place over a period of 
24-72 hours. Amastigotes are smaller (2-6μm), have a vestigial flagellum and are covered 
by a densely packed glycocalyx primarily composed of glycoinositolphospholipids and 
glycosphingolipids (34). Amastigotes are able to survive and multiply within the harsh, highly 
acidic (pH 4.0), environment of the phagolysosome, but maintain a neutral internal pH (15). 
When a sandfly takes a blood meal from an infected host, amastigote-containing 
macrophages can be ingested. Amastigotes are released in the sandfly midgut during 
digestion and begin the process of differentiation into promastigotes.  
 
Disease presentation 
Infection with Leishmania parasites can lead to a variety of clinical presentations in 
the infected host including cutaneous, diffuse cutaneous, muco-cutaneous or visceral 
leishmaniasis. Disease manifestation depends on the infecting Leishmania species and the 
immune status of the host.  Incubation periods can range from days to years and infection 
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can remain asymptomatic for the life of the host. Cutaneous leishmaniasis (CL) can present 
as a small erythematous nodule that develops at the site of the sandfly bite. This lesion 
progressively develops into an ulcer over a period of 2 weeks to 6 months. Ulcer 
development (size), progression (healing time), and clinical appearance (localized, diffuse, 
muco-cutaneous) differ from patient to patient (111). During localized CL, lesions can be 
large (up to 5 cm) and ulceration rarely penetrates into the subcutaneous tissue, except in 
the cartilage of the ear (4). These lesions are normally painless and often spontaneously 
self-heal resulting in lifelong protection from re-infection.  
Diffuse CL is the rarest and most severe manifestation of cutaneous disease (50).  
During diffuse CL, non-ulcerating lesions disseminate from the initial inoculation site and 
may affect the entire body. Lesion spread can occur locally or hematogenously and may 
result in deep tissue damage (4).  Diffuse CL is difficult to treat and patients do not self cure 
(111). In the case of muco-cutaneous leishmaniasis (MCL), hematogenous or lymphatic 
dissemination of the parasite affects the mucosal surfaces of the mouth, nose, and pharynx. 
MCL can manifest 1-5 years after localized CL has healed, although cases of concurrent 
localized CL and MCL have been reported (4, 111). MCL does not heal spontaneously, is 
severely disfiguring, treatment is very difficult and in certain cases, can potentially be fatal 
(111).  
Visceral leishmaniasis (VL), or kala azar, can manifest in a broad range of clinical 
spectrum from asymptomatic to chronic disease. Parasites primarily infect the 
lymphoreticular system, which can lead to life-threatening disease if left untreated. Classic 
clinical signs include lymphadenopathy, hepato- and splegnomegaly, pancytopenia, and 
hypergammaglobulinaemia, and renal disease (54).  
 
Treatment options 
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Several treatment options for leishmaniasis are available but their usage and efficacy 
depend on a variety of factors. These factors include parasite species, clinical presentation 
of the disease and the immune status of the host. While most localized cutaneous lesions 
self heal, drug therapy for cutaneous leishmaniasis (CL) is often used to increase healing 
time, reduce scarring and prevent potential parasite dissemination to other areas (111). For 
visceral leishmaniasis (VL), treatment is always recommended due to the fatal nature of the 
disease.  
The only treatment currently available for leishmaniasis relies on chemotherapy (33). 
Classical, first-line drug treatments include pentavalent antimonials compounds, 
stibogluconate (Pentostam, Glaxo-Smith-Kline) or meglumine antimonite (Glucantime). 
Pentavalent antimonials have been in use for more than 50 years and are the recommended 
treatment by the World Health Organization (WHO) (43, 54, 111). Other common drugs 
include amphoterecin B, pentamidine, imidazoles, allopurinol (Zyloric), miltefosine (Impavido 
or Miltex) and paromomycin among others.  
However, several obstacles remain in the treatment of leishmaniasis.  Most 
treatments require extensive (weeks to months) and invasive (intramuscular or intravenous) 
modes of administration and there is a high rate of significant drug-related toxic side effects. 
The cost of treatment is often well beyond the means of many patients and severe toxicity 
may require secondary treatment, adding to the already high cost of therapy (23, 111). 
These factors often deter many patients from continuing and completing their therapies. 
Most importantly, these drugs may only have selective efficacy as a result of drug-resistant 
parasite strains or patient immunosuppression, or may not be efficacious at all (4, 23, 54).  
While orally-available drugs (imidazoles, allopurinol, miltefosine) facilitated 
administration and have shown limited toxicity, their efficacy remains limited (4, 54). Non-
traditional, physical therapies including cryo- and thermotherapies are alternative treatment 
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options used for CL lesions (73, 112). However, they have not gained much recognition due 
to limited availability of equipment, increased secondary infections, parasite dissemination, 
and the appearance of larger scars following treatment (4).  
 Although a variety of drugs are available to treat leishmaniasis, treatment efficacy for 
MCL and VL remains subpar. In most cases parasites are never completely eliminated and 
disease recrudescence is very common. Additionally, the emergence of parasite resistance, 
increasing co-infections—especially with the increasing incidence of HIV—and the high cost 
of certain treatments all decrease the number of options available to patients. While current 
drugs all target the parasite itself, novel treatment options that target the parasite and work 
with the host immune response should be considered. Developing vaccines against 
Leishmania parasites has proven a difficult task and although a canine vaccine has been 
developed and it is in use in South America(reviewed in (32), at present no immunization 
options are available against leishmaniasis in humans.  
 
Visceral leishmaniasis  
 With an estimated 500,000 new cases of visceral leishmaniasis (VL) and 59,000 
annual deaths, VL is second only to malaria in annual worldwide fatalities due to protozoal 
infections (8, 132). Over 90% of VL cases occur in six countries: Bangladesh, India, Nepal, 
Sudan, Ethiopia, and Brazil (23). The main factors driving VL incidence include migration, 
urbanization, lack of vector and/or reservoir control measures, opportunistic co-infections, 
and civil war (8, 23).  
VL is caused by infection with L. donovani parasite species in East Africa and India, 
and by L. infantum infection in Europe, North Africa, and Latin America (23). Various 
Phlebotomous and Lutzomyia species of sandflies have been shown to transmit parasites in 
the Old and New Worlds, respectively. There are two types of VL, anthroponotic, transmitted 
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between humans and the vector, and zoonotic, transmitted from animal to vector to human. 
L. donovani transmission is anthroponotic while L. infantum is found in areas of zoonotic.  
Zoonotic visceral leishmaniasis (VL) is caused by L. infantum and both dogs and 
humans are natural hosts (115). In endemic regions, canine infection with L. infantum has a 
prevalence of 63-80% of the population, but shows a low rate of clinical disease (7). Infected 
dogs are considered the primary peridomestic reservoir for zoonotic VL and the most 
significant risk factor predisposing humans to L. infantum infection (23, 132). VL in dogs 
parallels both immunologic alterations and the pathophysiology of human disease (13). 
 
Host immune response to visceral leishmaniasis 
Host protection against VL requires a pro-inflammatory, T helper (TH) 1 immune 
response, as characterized by the production of interleukin (IL)-12 by antigen presenting 
cells and IL-2, tumor necrosis factor alpha (TNF-α) and interferon (IFN)-γ by T cells (94, 95). 
Infected macrophages are activated by IFN-γ and TNF-α to kill intracellular amastigotes via 
the L-arginine nitric oxide pathway (88, 93, 146). Cured or subclinical patients are able to 
mount antigen-specific IFN-γ responses following Leishmania antigen stimulation in vitro. 
Treatment-cured individuals can be resistant to re-infection and become leishmanin skin test 
positive, suggesting no inherent defect in the Leishmania-dependent TH1 response (19, 45, 
149).  
In experimental models of cutaneous leishmaniasis, susceptibility can be associated 
with a TH2 humoral-mediated immune response and production of IL-4 or the lack of a TH1 
immune response.   However, VL does not show a clear TH1/TH2 dichotomy pattern (137, 
138), as both TH1 and TH2 cytokine responses have been reported in both asymptomatic 
and symptomatic dogs (22, 122). One feature of susceptibility to developing clinical VL is the 
appearance of Leishmania-specific lymphoproliferative unresponsiveness and decreased 
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production of IFN-γ following Leishmania antigen stimulation (48, 120). This loss of 
lymphoproliferation and TH1 polarization can be attributed to the induction of an 
immunosuppressive response, geared towards preventing damaging immune-mediated 
pathology (84).  
Active disease in humans is associated with elevated IL-10 levels in serum and 
enhanced IL-10 mRNA in lesional tissues (47, 84). In canine VL (CVL), IL-10 production has 
been positively correlated with parasitic load and progression of clinical disease in naturally 
infected dogs (72). IL-10 is an immunoregulatory cytokine produced by a variety of cells 
including T cells, B cells, macrophages, and dendritic cells. The regulatory functions of IL-10 
extend to both innate and adaptive immune responses. IL-10 modulates the expression of 
inflammatory mediators, cytokines, and surface molecules in cells of myeloid origin, thus 
interfering with their ability to promote and maintain inflammatory responses (81). The 
presence of IL-10 is one factor that leads to a shift in the balance from a pro-inflammatory 
and effective immune response to a regulatory and dysfunctional immune response not 
capable of controlling disease progression.  
  Another immunological parameter associated with disease progression and 
suppression of the immune response to VL is hypergammaglobulinemia (109). Dogs with 
clinical disease produce higher levels of Leishmania-specific immunoglobulin (Ig) G as 
compared to clinically healthy dogs (2, 57, 132). In addition there is a correlation between 
high Leishmania-specific IgG levels and low Leishmania-specific cell-mediated immunity 
(41, 76, 95, 114).  Four IgG subclasses have been described in the dog (IgG1-4), with IgG1 
and IgG2 being the most studied in regards to CVL.  However, a relationship between IgG 
subclass profile and disease resistance versus susceptibility is unclear. Thus to date the role 
for IgG1 and IgG2 production during infection and disease development remains 
controversial (103, 109, 116).  
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Production of other immunoglobulins, such as IgM and IgA, is also increased in 
symptomatic dogs as compared to asymptomatic dogs (109, 116). However, no protective 
role of these antibodies has been shown. The overall increase in IgG, IgM, and IgA 
antibodies suggests the development of a strong but non-protective Leishmania-specific 
humoral immune response in dogs with clinical CVL.  
The mechanisms contributing to CVL susceptibility are not fully understood. It has 
been shown that certain dog breeds such as Boxers, Cocker spaniels, Rottweiler and 
German shepards seem to be more susceptible to disease, while other breeds such as the 
Ibizian hound are more resistant to CVL (132). Several genetic polymorphisms in TNF-α, 
certain MHC class II alleles, and solute carrier family 11 member a1 (N-RAMP1)—an iron 
and divalent cation antiporter involved in innate resistance to intraphagosomal pathogens—
have been associated with susceptibility (65, 104). Other factors such as age, gender, 
nutrition, co-infections, immunosuppressive conditions, parasite burden, virulence of 
Leishmania strain, previous infections and mode of transmission can affect the course of 
disease development (132).   
 
Canine visceral leishmaniasis in the United States 
Although VL is not endemic in the United States (US), canine visceral leishmaniasis 
(CVL) has recently been described in this country within the Foxhound population. The most 
recent outbreak of CVL in the US occurred in 1999 in a foxhound kennel in New York (46). 
By 2005, it was reported that 60 kennels in 22 states and two Canadian provinces had L. 
infantum-seropositive Foxhounds, and that autochthonous infection in canines was limited to 
the Foxhound population (38).  
Disease transmission within the Foxhound population has not been shown to be 
vector-dependent. Fourteen species of Lutzomyia sandflies are found within the United 
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States, of which three (Lutzomyia anthopora, Lutzomyia diabolica, and Lutzomyia shannoni) 
can transmit at least one Leishmania species, L. mexicana (66). Lutzomyia shannoni could 
serve as a potential vector for L. infantum and is currently found in the Southern, 
Midwestern and Southeastern US (38). Anecdotal data indicates that Lutzomyia shannoni 
sandflies within the US can become infected with L. infantum, however whether these flies 
can support metacyclogenesis (parasite development within the insect vector) and transmit 
infection is still unknown.  
Other means of transmission have been postulated for autochthonous CVL in the 
United States including horizontal (dog to dog) and vertical (transplacental or 
transmammary) mechanisms.  Transmission via packed red blood cell transfusions from 
infected foxhounds have been documented (87). Housing practices in Foxhound kennels 
place large numbers of animals together where potential horizontal transmission (direct 
blood to blood contact) can occur. Transplacental transmission in Beagles after 
experimental infection with L. infantum has been reported (117) and recently, transplacental 
transmission in L. infantum and L. chagasi naturally-infected dogs in endemic countries has 
been shown (30, 89). Analysis of fetal tissues from symptomatic and asymptomatic female 
dogs revealed the presence of L. chagasi amastigotes via immunodetection and PCR, 
indicating that vertical transmission does occur. Our own studies have shown, via PCR, the 
presence of L. infantum DNA in multiple tissues of neonatal puppies (lymph nodes, bone 
marrow, liver, lung, thymus and spleen) born to a sero-positive, L. infantum-infected 
Foxhound female (unpublished data).  
Despite potential alternative modes of transmission, the clinical presentation and 
disease pathology of infected Foxhounds is equivalent to that of infected dogs in endemic 
areas (49). Physical examination findings of infected Foxhounds include depression, loss of 
muscle mass, mildly distended abdomen, epistaxis, dull hair coat, hepatosplenomegaly and 
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generalized lymphoadenopathy, consistent with findings in endemic regions (reviewed in 
(132)). Clinical findings including decreased hematocrit, thrombocytopenia and signs of 
renal failure and hepatic compromise (reviewed in (92)). Gross and histopathological 
examination of tissues from infected Foxhounds in the US revealed  liver and spleen 
enlargement, systemic lymphoadenopathy, glomerulonephritis, and the presence of 
Leishmania amastigotes in a variety of tissues (13, 49). 
While CVL presentation and pathology in Foxhound mirrors disease in endemic 
regions, to date, the host immune response to natural L. infantum infection in the US has not 
been described. The Foxhound model of CVL not only presents a unique opportunity to 
study the host immune response to L. infantum infection in a traditionally non-endemic 
region, but also under conditions of non-vector transmission.  
 
Cutaneous leishmaniasis  
 The number of human cutaneous leishmaniasis cases globally has increased in the 
last decade as documented both in the Old and New Worlds (111). Approximately 350 
million people are at risk for infection with a world-wide prevalence of 12 million and an 
annual incidence of 1.5 million cases of CL (4). The increased number of cases can be 
explained, in part, by improved diagnostics. However, inadequate vector and/or reservoir 
control, CL associated with opportunistic co-infections, and the emergence of anti-
leishmanial drug resistance have contributed to the observed increased dissemination of CL 
(111). Increased incidence of CL can also be attributed to migration of people into or from 
endemic areas, deforestation and urbanization, tourism, natural disasters, armed conflict 
and global warming—allowing spread of vector habitat (4, 54, 111, 125).  
 CL is primarily found in Africa, Asia and in Latin American countries. In the Old World 
several species of Leishmania can cause CL including L. major, L. aethiopica and 
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dermotropic L. infantum (50), with L. major having the largest geographical distribution. L. 
major is widely distributed in arid and savannah regions, surviving in several rodent 
reservoirs. Plebotomous species are well characterized vectors for L. major, with P. papatasi 
acting as the principal vector. Infection with L. major primarily causes localized, self-healing 
CL. Epidemics of CL caused by L. major were reported in endemic countries in the 1980s 
and coincided with rodent migrations or fluctuations in rodent populations (50).  
 In the New World, over 11 species of Leishmania have been characterized as 
causative agents of CL, including L. amazonensis, L. braziliensis and L. panamensis. L. 
amazonensis has one of the widest geographical distributions affecting Brazil, Bolivia, 
Colombia, Ecuador, Peru, French Guyana, Panama and Venezuela (50). Forest rodents are 
the main reservoir, with marsupial species acting as secondary hosts. L. amazonensis 
parasites are mainly transmitted by Lutzomyia flaviscutellata. Infection with L. amazonensis 
can cause localized or diffuse CL and unlike most cases of L. major infection, L. 
amazonensis can result in non-healing chronic disease.   
 
Murine cutaneous leishmaniasis: TH1/TH2 balance? 
Protective immunity against Leishmania infection in mice is dependent on the 
development of a TH1 cell mediated immune response (reviewed in (118)). This is 
characterized by the production of interleukin (IL)-12 by antigen presenting cells (APC), 
interferon gamma (IFN-γ)-producing CD4+ T cells and activation of macrophages to produce 
nitric oxide (NO) and peroxinitrite to eliminate intracellular parasites.  Classically, disease 
susceptibility in mice is thought to result from the induction of TH2 responses, characterized 
by APC that fail to produce IL-12 but release IL-4 or IL-10, leading to the priming of IL-4-
producing CD4+ T cells, resulting in alternatively-activated macrophages that do not 
effectively promote parasite killing.  
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Studies of murine models of L. major infection provided the first direct evidence of 
the importance of TH1/TH2 balance to the regulation of disease resistance versus 
susceptibility (108, 118). Early studies in this field demonstrated the role for CD4+ T cells 
and the production of IFN-γ as key regulators of resistance and parasite clearance (55, 74). 
Via an adoptive transfer model, it was shown that while TH1 cells protected susceptible mice 
from L. major infection, TH2 cells promoted disease (126). This protective response was 
directly linked to the production of IFN-γ, as depletion of this cytokine in vivo led to disease 
susceptibility, while neutralization of the TH2 cytokine IL-4 led to increased resistance in 
susceptible mice (10, 52). 
Infection of either L. major resistant (C3H and C57BL6) mouse strains with L. 
amazonensis results in non-healing, chronic disease. The immune response associated with 
susceptibility to L. amazonensis infection is not dependent on the development of a TH2 type 
of immune response, but rather the lack of a TH1 immune response. Infection with L. 
amazonensis shows low to undetectable levels of both IFN-γ and IL-4 (1, 61). In these 
animals, susceptibility is thus associated with the absence of an efficient TH1 immune 
response rather than the presence of a TH2 response. The lack of a TH1 response persists in 
the absence of IL-4 and IL-10. Treatment with exogenous IL-12, a TH1-polarizing cytokine, 
to promote parasite clearance also fails to promote healing (1, 60, 61). Furthermore, 
analysis of antigen-responsive CD4+ T cells from C3HeB/FeJ mice chronically infected with 
L. amazonensis, indicate that these cells have an impaired ability to transition from a naïve 
to an effector phenotype (106). Altogether, these data suggest that while a population of 
antigen-specific CD4+ T cells are present during L. amazonensis infection of C3HeB/FeJ 
mice, improper TH1-polarized priming may responsible for the non-healing phenotype. 
 
Promoting a TH1 immune response 
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The induction of protective TH1 cell-mediated immune responses is driven by the 
cytokine IL-12, a heterodimer composed of p35 and p40 subunits. During the initiation of an 
immune response, IL-12 is produced by antigen-presenting cells (APC), such as 
macrophages and dendritic cells (DC). While p35 is expressed constitutively at low levels, 
p40 gene expression is inducible in response to microbial stimuli via engagement of Toll-
Like Receptors (TLR) (143, 148) and activation of nuclear factor-κB (NF-κB) family 
members.  IL-12 binds the IL-12 receptor (IL-12R) complex composed of IL12-Rβ1 and IL-
12Rβ2, and signals through the transcription factor STAT4 to mediate biological responses. 
IL-12 plays a critical role in the priming of naïve T cells to proliferate and differentiate into 
TH1 cells that secrete IFN-γ (148). In addition, production of IL-12 prevents TH2 polarization 
and the production of TH2-related cytokines.   
However, microbial signals alone are not enough to trigger production of the 
bioactive IL-12 heterodimer. Additional activating signals are necessary to enhance its 
production, including IFN-γ secretion and direct cell to cell contact (82, 143, 148). One such 
cell to cell interaction occurs via the secondary receptor CD40 expressed on the APC and 
CD40 ligand (CD40L) expressed on the surface of lymphocytes. CD40 is a 43-50kDa 
protein belonging to the tumor necrosis factor (TNF) family of receptors originally identified 
on B cells.  It is now known that CD40 is widely expressed by a variety of cell types including 
monocytes, DC, hematopoietic progenitors, endothelial and epithelial cells (124). CD40-
CD40L interaction is a bidirectional event providing activating signals to both APC and 
lymphocytes (91). CD40-CD40L stimulation promotes T cell proliferation and IL-2 and IFN-γ 
production and enhances the production of cytokines from APCs, including IL-12 via 
activation of the nuclear factor-kappa B (NF-κB) pathway (91, 153).  
The role of IL-12 during Leishmania infection has been extensively studied and 
deficiencies in IL-12 or IL-12R subunits are associated with disease susceptibility to L. major 
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infection in genetically-resistant mouse strains (21, 78). IL-12 is also required not only in the 
initiation but also in the maintenance of TH1 immune response to L. major infection (90).  
Genetic deficiencies in CD40 or CD40L have proven to be detrimental to the host 
during the initiation of protective immune responses against both intracellular and 
extracellular pathogens (77). These findings indicate the importance of CD40 in activating 
both TH1 and TH2 responses to provide host protection against infection. Several reports 
have shown that during Leishmania infection the absence of CD40 or CD40L results in 
disease susceptibility (17, 63, 133) owing to decreased IL-12 production and an inability to 
mount a protective TH1-mediated immune response.  
   
 Dendritic cell biology 
Dendritic cells (DC) are unique antigen presenting cells (APC) because of their 
efficiency in translating innate immune messages into adaptive immunity (6, 110, 136). 
These messages can be either immunogenic or tolerogenic in nature. The properties that 
allow these cells to perform different activities rely on the ability of DC to sense their 
environment via antigen-sampling, appropriately respond to activating cues, and deliver 
messages during antigen (Ag) presentation to T cells.  
DC are classically described as being either immature or mature, referring to both 
phenotypic and functional characteristics.  A key feature of immature DC is their ability to 
efficiently capture Ag (80) via a variety of pathways including macropinocytosis, receptor-
mediated endosytosis and phagocytosis (5). Ag is taken up and targeted to major 
histocompatabililty complex (MHC) class II-positive lysosomes, where it will be retained for 
future use as immunogenic peptides (56, 144). Upon Ag encounter, immature DC undergo 
phenotypic and functional changes, collectively known as DC maturation. These changes 
 
 
18 
 
will provide the “immunological context” under which adaptive responses—immunogenic or 
tolerogenic—will be initiated.  
Mature DC have a reduced capacity for Ag uptake, but have an enhanced ability for 
Ag presentation, and therefore, greater capacity for priming immune responses (5, 6). This 
process is characterized by their ability to generate functional peptide-major 
histocompatability complex (MHC) class II complexes (56, 144), redistribute these 
complexes to the plasma membrane, upregulate surface co-stimulatory molecules (i.e. 
CD40, CD80, and CD86) and produce APC-related factors (i.e. cytokines) (5). These 
changes transform DC from an Ag-sampling cell to an Ag-presenting cell, able to promote 
the expansion and differentiation of T cells into appropriate effector cells (110). The 
maturation process also results in upregulation of chemokine receptors that facilitate DC 
migration into secondary lymphoid organs where encounter with naïve T cells will occur.  
During DC-T cell interactions, three signals are delivered from the APC to the naïve 
lymphocyte. The first activating signal, ‘signal one’ is delivered during peptide-MHC binding 
to cognate T cell receptors (TCR). This signal transmits the molecular identity of the Ag and 
determines the specificity of the response (59, 62, 64). Co-stimulatory molecules on the 
APC, such as CD40, deliver ‘signal two’ by engaging counter-receptors on the T cell. This 
second signal is critical for T cell survival and proliferation, as in the absence of co-
stimulatory signals, antigen presentation via the TCR leads to anergy or deletion (64). The 
third signal is delivered by mediators produced by DC, such as cytokines, and provides 
polarization of the immune response (27, 59).   
 
Dendritic cell subsets 
In the bone marrow, two progenitors have been shown to give rise to DC, lymphoid 
and myeloid.  The DC population that arises from these progenitors is a sparsely distributed, 
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heterogenous population composed of multiple subtypes of DC with distinct life spans and 
functions (150). In the steady-state, myeloid progenitors give rise to immature DC that 
migrate through the circulation into peripheral tissues and become resident DC, also known 
as conventional DC (cDC). cDC can be further characterized into different subsets 
depending on their location: Langerhans cells in the skin, mucosal-associated DC in 
mucosal tissues, interstitial DC in the interstitial spaces of an organ, lymphoid-tissue 
associated DC, etc. Myeloid progenitors may also give rise to monocyte-derived DC and 
tumor necrosis factor (TNF)-producing and nitric oxide synthase (iNOS)-expressing DCs in 
response to inflammation (5, 27, 150). Lymphoid progenitors give rise to all DC subtypes in 
the lymphoid tissues and to type I interferon-producing plasmacytoid DC (pDC).   
   
T cell polarization 
Given the different DC subsets that have been characterized and the distinct 
microenvironment where they reside, it was proposed that DC function was pre-determined 
by lineage. Several initial studies suggested that distinct DC subsets might regulate TH 
responses differentially, more specifically, that myeloid-derived DC preferentially primed TH1 
responses while lymphoid-derived DC primed TH2 or tolerogenic responses (27, 101). 
However, this data was later challenged by reports showing that DC had a high degree of 
functional plasticity in response to pathogens, and that their ability to induce TH1 versus TH2 
responses was dependent on the nature of the microbial stimulus, various environmental 
factors (i.e. local inflammatory or anti-inflammatory mediators), tissue of residence, and in 
vitro culture conditions under which DC were being studied. These data suggested that 
while genetic pre-programming may affect the TH polarizing function of DC to an extent, the 
dynamic environment under which DC become activated affects its effector phenotype and 
the ensuing adaptive immune response (62).   
 
 
20 
 
It is now clear that immature DC can become mature DC with different effector 
functions capable of priming distinct T cell fates including T helper as well as T regulatory 
responses (110). This is largely determined by environmental stimuli, both of exogenous 
(microbial) and of endogenous origins (cytokines, chemokines, hormones, apoptotic/necrotic 
cells) in which DC become activated. Alteration of DC function can enhance pathogen 
survival and persistence within the host. Suppression of DC maturation, antigen 
presentation, and altered DC migration have been shown to be modulated by pathogens 
including Leishmania parasites (reviewed in (119). 
 
Signals that trigger DC maturation 
 Dendritic cells express a variety of pattern recognition receptors (PRR) on their 
surface responsible for sensing the presence of pathogens. The stimuli received through 
ligand-receptor interactions trigger signaling pathways that mediate host-cell responses (i.e. 
maturation) and can alter the biological response of the host (67). The balance of particular 
molecular signaling cascades has been shown to affect the maturation process of DC (5, 26, 
113). Two such pathways are the NF-κB and mitogen activated protein kinase (MAPK) 
signaling cascades. MAPK pathways terminate in three primary kinases, p38, c-Jun N-
terminal kinase (JNK) and extracellular signal-regulated kinase (ERK1/2). Activation of NF-
κB, p38 and JNK positively regulate DC maturation and promote the production of a variety 
of inflammatory cytokines including TNF-α, IL-1, IL-6 and IL-12 (154). In contrast, activation 
of the ERK1/2 pathway negatively regulates DC maturation resulting in decreased 
expression of maturation markers and production of pro-inflammatory cytokines (100, 113). 
ERK1/2 activation can also enhance release of IL-10 from DC promoting a pro-tolerogenic 
DC phenotype (18).    
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The Mitogen Activated Protein Kinase Pathway  
 The mitogen activated protein kinases (MAPK) are a family of intracellular kinases 
involved in the regulation of a wide variety of cellular processes including embryogenesis, 
cell differentiation, proliferation, migration, apoptosis, and innate and adaptive immune 
responses. There are three main families of MAPK, the extracellular signal-regulated 
kinases (ERK) 1 and 2 (Figure 2), the stress-activated protein kinase (SAPK) 1, also known 
as the c-Jun N-terminal Kinase (JNK1-3), and the SAPK-2, p38α/β/γ.  
All MAPKs consist of a Thr-X-Tyr motif in their activation loop, and phosphorylation 
of both threonine and tyrosine residues are required for their activation (154). 
Phosphorylation of MAPK is accomplished through a triple kinase cascade. Dual 
phosphorylation of MAPK is carried out by upstream MAPK kinases (MKKs), which are dual-
specificity kinases that themselves are activated by MKK kinases (MKKKs) via 
phosphorylation of their Ser/Thr residues (154).  
Despite the simple architecture of MAPK activation, these pathways can respond to 
a variety of stimuli leading to different and specific outcomes in gene expression and 
ultimately cellular function. While it is not completely understood how these responses are 
fine-tuned, it has become clear that signal kinetics (activation/deactivation), subcellular 
localization, substrate availability, and the formation of signaling complexes play a role in 
this regulation (105, 152, 154).  
 
Raf-MEK1/2-ERK1/2 Pathway 
ERK1/2 are ubiquitously expressed 44 and 42kDa proteins activated by a variety of 
stimuli including growth factors, serum, ligands for heterotrimeric G-coupled protein 
receptors (GPCR), cytokines, stress factors, microtubule depolymerization, and pattern 
recognition receptors (PRRs) (24, 105, 154). ERK1/2 is also ubiquitously distributed 
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intracellularly and found to be associated with plasma membrane receptors and 
transporters, cytoplasmic microtubules, and on intracellular compartments (i.e. Golgi, 
endosomes). In addition to the microtubule cytoskeleton, ERK1/2 interactions with its 
upstream kinase, MEK1/2, have been shown to play a critical role in maintaining 
cytoplasmic distribution of ERK1/2 (105).  
Activation of ERK1/2 requires dual phosphorylation which is exclusively carried out 
by the upstream MKKs, MEK1 and MEK2. MEK1/2 contain a kinase domain which itself 
requires dual phosphorylation on both serine and threonine residues for their activation. In 
addition to its kinase domain, MEK1/2 contains three non-enzymatic domains necessary for 
their function: an ERK1/2 binding domain, a proline-rich domain, and a nuclear export 
sequence (NES). The ERK1/2 binding domain, also known as a D domain, interacts with 
common docking (CD) motifs on ERK. These CD motifs are necessary for ERK regulation 
as mutations that modify or delete this domain not only interfere with ERK phosphorylation 
they also affect subcellular distribution of ERK (24). The proline-rich domain is absent from 
other MEK family members and may serve as docking sites for other proteins, including 
scaffolding proteins MEK partner 1 (MP1). The NES of MEK1, as mentioned above, plays a 
critical role in maintaining cytoplasmic distribution of ERK2.  
Dual phosphorylation of MEK1/2 is carried out by the MKKK, RAF. All isoforms of 
RAF, A-RAF, B-RAF, C-RAF and Raf-1 have been shown to activate the ERK1/2 pathway. 
RAF appears to be the major, if not the exclusive, activator of MEK1/2. However, RAF-1 is 
the most widely distributed protein and the most commonly studied (24, 105, 154). In its 
inactive state, RAF is found in the cytosol and bound to regulatory proteins (14-3-3 and 
possible connector enhancer of KSR (CNK)) maintaining RAF as a closed, catalytically 
inactive form (107). Upon stimulation, RAF translocates to the plasma membrane where it 
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can interact with GTP-loaded RAS. This interaction causes conformational changes leading 
to the release of the regulatory proteins, and subsequent activation (85, 107).   
 
MAPK pathway and therapeutic intervention  
A large number of cellular processes are regulated by the RAS-MAPK pathway and 
aberrant signaling through this cascade has been associated with a variety of conditions 
from cancer to inflammatory diseases (reviewed in (128)). The central role of MAPK in 
regulating cell growth and survival has made this pathway an attractive target for anti-cancer 
therapies. Due to the specificity of the RAS-RAF-MEK signaling components, it is possible to 
selectively inhibit this pathway without affecting other MAPK signaling cascades.  
 Pharmacological interventions are now focusing on exploiting the unique properties 
in these signaling cascades. Small-molecule inhibitors are low molecular weight organic 
compounds that bind proteins, nucleic acids, or polysaccharides with high affinity. Their 
small size, no bigger than 800 Daltons, allows these molecules to easily diffuse through cell 
membranes and reach targets within intracellular sites. Small-molecule inhibitor drugs are 
currently being utilized to target RAS, RAF and MEK for therapeutic intervention. Several 
small-molecule, non-ATP binding inhibitors have been developed for MEK inhibition, starting 
with PD98059 to the more recently, orally-available inhibitors CI-1040 and its related 
compounds (37, 127, 128).  
Currently a variety of small-molecule inhibitors for the Ras-MAPK pathway are 
available for anti-cancer treatment and several more are undergoing clinical trials.  These 
inhibitors can potentially be utilized in the treatment of other diseases, including infectious 
diseases, whose pathogenesis is mediated by the MAP kinase pathways. However, given 
the large repertoire of MAP kinase ERK substrates including transcription factors, kinases, 
phosphatases, cytoskeletal proteins, apoptotic proteins, and others (152), one important 
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aspect in the development of new therapeutic drugs is the idea of targeting specific signals 
within this pathway, rather than global suppression of ERK activation. Recently, scaffolding 
proteins have been described, which regulate the temporal and spatial regulation of ERK 
signaling (reviewed in (14, 35, 70)). These findings have raised interest in utilizing scaffold 
proteins as therapeutic targets.   
 
Leishmania host cell interactions 
Modulation of DC maturation   
Studies of low dose infection in mice with L. major promastigotes revealed an 
immunologically silent phase of infection before the onset of an immunological response. 
During this time, parasite replication occurred with minimal production of IL-12 or IFN-γ 
suggesting the absence of an ongoing immune response (9). These data corroborated in 
vitro studies showing that Leishmania could actively inhibit immune activation of their host 
cells including Ag-presentation, and decreased expression of both MHC class II and co-
stimulatory molecules (CD80, CD86, CD54, and CD40) (11, 39, 68, 97, 98, 121). 
Leishmania spp. can also differentially regulate cytokine production by infected DC. While 
infection with L. major leads to the secretion of IL-12, infection with L. donovani and L. 
tropica leads to inhibition of IL-12 production in response to activating stimuli such as 
lipopolysaccharide (LPS) and IFN-γ (79). L. amazonensis internalization via Fc receptors 
results in the release of anti-inflammatory cytokines such as IL-10 (147). Altered migration 
has also been reported following infection with L. major in vitro (58, 96). Decreased DC 
migration has also been observed in vivo following L. donovani infection, as a result of 
decreased expression of the chemokine receptor CCR7 (3). 
 
Leishmania modulation of host cell signaling pathways 
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Leishmania parasites have been shown to alter host-cell signaling pathways to 
promote their survival. Activation of host Src homology 2 domain (SH2) containing tyrosine 
phosphatases (SHP-1) by Leishmania infection results in global dephosphorylation of 
tyrosine residues, leading to deactivation of a variety of signaling pathways including 
JAK/STAT, NF-κB, IRF-1, and MAP kinases (reviewed in (67, 86)). Increased concentrations 
of secondary messengers including calcium (Ca2+), inositol lipids, inositol phosphatases, 
and PKC have also been observed following Leishmania infection. Induction of the negative 
regulatory proteins, suppressors of cytokine signaling (SOCS), have been characterized 
following L. donovani infection and interfere with cytokine signaling and host cell activation 
(12). L. mexicana cysteine peptidases have been shown to degrade NF-κB leading to 
modulation of this pathway (16). Proteosome-mediated degradation of signaling 
components, specifically STAT1α, has also been observed to play a role in Leishmania-
mediated modulation of host signaling pathways (42). More recently, cleavage of the NF-κB 
p65 subunit by the Leishmania proteolytic glycoprotein (gp) 63 has been observed following 
L. donovani, L. major, L. mexicana, and L. braziliensis infection of macrophages in vitro (51).  
Most studies aimed at understanding the regulation of signaling pathways triggered 
by Leishmania parasites have focused on the initial events of host-parasite interactions. 
However, Leishmania parasites reside intracellularly within parasitophorous vacuoles (PV) 
and it is from within these intracellular compartments that parasites continue to engage cell 
signaling pathways and alter the host’s biological responses (67). This has been 
demonstrated by the presence of products of the phosphoinositide 3-kinase (PI3K) pathway 
on PV following L. amazonensis infection. This observation suggests that these organelles 
could serve as activation sites for downstream kinases of this pathway, such as protein 
kinase (PK)B/Akt (67). 
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Signaling from endosomes 
The endocytic pathway 
 Entry into host cells through the endocytic pathway is a common feature of most 
intracellular pathogens, including Leishmania. Some pathogens enter the endocytic pathway 
via phagocytosis, an endocytic pathway through which large particles (>0.5μm in size) are 
internalized and contained within membrane-bound organelles known as phagosomes. 
Internalized material via phagocytosis follows a pre-determined pathway ultimately leading 
to the degradation of its content. This process known as phagosome maturation results in 
the sequential acidification of these compartments, ultimately leading to fusion of 
phagosomes with lysosomes. The stages of phagosome maturation  can be classified and 
tracked via their associations with Rab proteins (GTPases), lipids (phosphoinositides), and 
glycoprotein (lysosomal-associated membrane protein LAMP) composition which not only 
phenotypically distinguish between different maturation stages, but are also important in the 
maturation process (69). 
The parasitophorous vacuole (PV) in which Leishmania resides is composed of host 
plasma membrane, phagosomal organelles, and parasite-derived molecules (53). PV 
display phagolysosomal features characterized by a highly acidic luminal pH, the presence 
of proteases, phosphatases, and cytosolic surface expression of Rab7, LAMP1 and LAMP2 
(29, 71). These organelles are highly dynamic in their structure and composition. Acquisition 
of endosomal components—and their content—is an ongoing process, as fusion of newly 
internalized materials and recycled cytoplasmic molecules are delivered into lysosomal 
compartments, including Leishmania-containing PV (15). Based on recent work suggesting 
the important role of endocytosis in signal transduction (reviewed in (134)), signaling 
components (i.e. extracellular receptors, lipids, kinases, adaptor and scaffold proteins) could 
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be delivered to parasite-containing PV. Once associated with PV it is feasible that these 
signaling molecules could be utilized by the parasite to trigger signaling cascades.  
 
Endosomal signal transduction 
Receptor internalization upon ligand binding is a common regulatory mechanism for 
receptor desensitization (134). A variety of receptors including G-protein coupled receptors 
(GPCR) and receptor tyrosine kinases (RTK) are rapidly internalized upon ligand binding 
and are either recycled back to the plasma membrane or sent to lysosomes for degradation. 
Although this process was initially thought to play a role in signal attenuation, the presence 
of activated epidermal growth factor receptors (EGFR) and downstream effectors on 
endosomes, first suggested the possibility of signaling from endosomes (36). The idea of 
endosomes serving as signaling platforms for RTK and GPCR has since been strengthened 
by subsequent studies showing the myriad of signaling proteins found associated with 
endosomal compartments, attenuated activation of signaling pathways when endocytosis is 
inhibited or when endosomal compartments are mis-localized inside the cell (reviewed in 
(31, 135)) (139, 145).  
Most of these studies have focused on the activation of the mitogen-activated protein 
kinases (MAPK) pathway ERK1/2 following RTK or GPCR trigger. ERK1/2 activation has 
been shown to occur both at the plasma membrane and from within endosomal 
compartments following receptors internalization (reviewed in (134)). The presence of 
activated MAP kinases on endosomal membranes and the distinct pattern of ERK activation 
from this subcellular location (140) supported the concept that intracellular signaling could 
serve to control MAPK signal specificity. The characterization of scaffold proteins provided a 
mechanism for the recruitment and subcellular localization of MAPK signaling components.    
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Scaffold proteins in signal transduction regulation   
 Scaffolding proteins are molecules that can bind to two or more signaling proteins, 
regulate signal transduction, and localize signaling molecules at specific sites within the cell 
(i.e. plasma membrane, golgi, endosomes). The first scaffolding proteins to be identified 
were characterized using receptor tyrosine kinases, platelet-derived growth factor receptor 
(PDGFR) and epidermal growth factor receptor (EGFR) (28). These initial studies showed 
recruitment of then unidentified proteins that bound to phosphorylated SRC homology 2 
(SH2) domains on the intracellular domain of the receptors. These sites appeared to serve 
as docking or scaffolding domains for other proteins and/or substrates. The proteins 
recruited at these sites were hypothesized to determine the strength and type of signal 
triggered.  
 At least four different functions have been characterized including the idea that these 
proteins serve as platforms for assembly of signaling cascades, coordinate positive and 
negative feedback signals, compartmentalize signals to specific sites within the cell, and 
protect activated molecules from inactivation or degradation (131). Although further roles of 
many scaffold proteins are not yet understood, in general, scaffold proteins may provide a 
critical level of regulation during signal transduction shedding light on how cells can 
differentiate between messages within an ubiquitous signaling cascade.  
 
Scaffolding proteins of the MAPK ERK Pathway 
 Scaffolding proteins in the MAPK signaling pathway were first identified in the 
budding yeast S. cervisiae (reviewed in (35)). Using the pheromone signaling mating 
response as a stimulus, activation of the S. cervisiae equivalent of the MAPK pathway was 
analyzed, revealing the requirement of a protein encoded by Ste5. In its absence, activation 
of this pathway was abolished (25, 75, 99). Yeast-two-hybrid analysis and co-purification 
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studies indicated that the different domains of Ste5 specifically interact with Ste11, Ste7 and 
Fus3 (MAP3K, MAP2K, and MAPK) forming a signaling module that provides specificity to 
the mating signal by co-localizing Ste11-Ste7-Fus3 and optimizing the orientation of Ste11 
so as to be phosphorylated by its upstream kinase (40, 102).  
 To date seven different scaffold proteins have been identified in the regulation of 
ERK1/2 signaling: IQ motif-containing GTPase-activating protein 1 (IQGAP1), kinase 
suppressor of Ras (KSR), β-arrestins, paxillin, similar expression of FGF (Sef),  MEK 
partner-1 (MP1), and MAPK organizer 1 (MORG1). Compartmentalization in MAPK/ERK 
signaling has emerged as a critical component in the spatial arrangement and regulation of 
this pathway (14, 70). The importance of compartmentalization is highlighted by the variety 
of these scaffold proteins involved not only in localization but also regulating 
nucleocytoplasmic distribution of activated MAPK/ERK (70). 
 KSR (Figure 3) is one of the best characterized scaffold proteins of the MAPK 
signaling cascade, interacting with c-Raf, MEK1/2 and ERK1/2 (14). Association with MEK is 
constitutive while interaction with ERK1/2 occurs only after stimulation. KSR localizes to the 
plasma membrane, thus regulating extracellular activation of the MAPK pathway. Studies in 
KSR-deficient mice have revealed a defect in cytokine production, peripheral T cell 
proliferation, and defective activation of ERK in response to TNF-α and IL-1 stimulation (44). 
KSR enhances the generation of activated/phosphorylated ERK, which can phosphorylate 
both nuclear and cytoplasmic substrates.  
 β-arrestins are known regulators of G protein coupled receptors (GPCRs). β-
arrestins have been shown to interact with Raf, MEK, and ERK, and recruit these proteins to 
the activated receptor. β-arrestins promote the internalization of GPCRs and recruitment of 
MAPK signaling components to early endosomes (142). Interestingly, MAPK activation via 
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β-arrestin association leads to cytosolic activation of ERK1/2, but does not promote its 
nuclear translocation (14).  
 MP1 (Figure 3) is a widely expressed scaffold protein for ERK1/2 signaling originally 
isolated from a two-hybrid screen conducted to identify non-enzymatic components of the 
MAPK signaling cascade (123). MP1 is a 13.5kDa protein that specifically interacts with 
MEK1 and ERK1, but not MEK2 or ERK2. MP1 was shown to co-localize with late 
endosomes via the adaptor protein p14, which is associated with the cytosolic side of late 
endosomes (151). More recently, the lipid raft adaptor protein p18 has been identified as an 
anchor for the p14-MP1-MEK complex on late endosomes (83).  
While in vitro studies have shown that MP1, p14, and p18 can augment MEK1 
phosphorylation and therefore subsequent ERK1 phosphorylation, the importance of these 
adaptor and scaffold proteins in ERK signaling are evident as depletion of any of these 
proteins leads to deficiencies in ERK activation and kinase activity. Using epidermal growth 
factor (EGF) stimulation, it has been demonstrated that silencing of MP1 and p14 via short 
interfering (si) RNA leads to reduced activation of ERK1 (141). In the absence of MP1, p14 
does not interact with MEK1 or ERK1 and in the absence of p14, MP1 is mis-localized to the 
cytoplasm, leading to decreased phosphorylation of ERK from late endosomes.  In p18-/- 
cells, the p14-MP1 complex is excluded from late endosomes, again resulting in decreased 
ERK activation from these compartments (83). Plasma membrane-mediated activation of 
ERK following EGF stimulation is not affected by the absence of MP1, p14 or p18, further 
demonstrating the role of these proteins in the endosomal-mediated activation of ERK. 
 Similar to MP1, MORG1 (Figure 3) was characterized via a two-hybrid screen in 
order to identify binding partners for MP1 (129). MORG1 can also associate with Raf-1, B-
Raf, MEK1/2, and ERK1/2. MORG1 appears to mediate MAPK signaling in response to 
GPCR-triggering, and not RTKs, making the role of MORG1 scaffold protein ligand/receptor-
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specific. MORG1 enhances ERK activation in response to lisophosphatidic acid (LPA), 
phorbol ester, and serum but not in response to EGF stimulation (129). Recruitment of 
MORG1 to late endosomes and its association with MP1 may provide an additional level of 
regulation from upstream activators.  
 The additional level of regulation provided by specific scaffold proteins during signal 
transduction provides a very specific target for modulation of signaling pathways. The 
myriad of scaffold proteins characterized within the ERK pathway provide a unique 
activation environment that leads to a specific cellular function. Targeting of these scaffold 
proteins (upregulation or downregulation) may enable direct and specific modulation of ERK 
activation. Therapeutically, this can lead to very specialized, effective treatment options 
where regulation of ERK signaling only occurs under pathological cascade stimulation, 
without affecting steady-state ERK function.  
 
Overview of this thesis  
 Infection with Leishmania infantum and Leishmania amazonensis lead to very 
different, yet chronic, disease manifestations. While infection with L. infantum may initially 
promote an effective CD4+ TH1 immune response, disease progression has been correlated 
to the appearance of an immuno-suppressive response. In contrast, infection with L. 
amazonensis does not promote a clear TH1/TH2 polarization, and more rapidly results in a 
tolerogenic response.  The factors that promote chronic disease following Leishmania 
infection and the mechanisms utilized by these parasites to modulate the adaptive immune 
response remain poorly understood. The objectives of this dissertation are to characterize 
immune parameters that could be indicative of immune dys-regulation and therefore disease 
progression following L. infantum infection, to understand the L. amazonensis-mediated 
modulation of dendritic cell maturation phenotype that could lead to the induction of a non-
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polarized immune response, and to characterize the molecular mechanism by which L. 
amazonensis triggers endosomal activation of ERK1/2.  
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Figure 1 Life cycle of Leishmania major infection. Leishmania parasites are transmitted 
by the bites of infected female sandflies, which inject a small number of infectious-stage, 
metacyclic promastigotes into the skin. These forms are opsonized efficiently by serum 
components and taken up by macrophages, where they reside in phagolysosomes and 
transform into replicating amastigotes. Infected macrophages are taken up by sandflies 
during blood feeding; they are lysed in the fly midgut, releasing parasites that transform into 
rapidly dividing, non-infectious-stage promastigotes. These forms undergo a process of 
attachment to the midgut wall, release and anterior migration that is accompanied by their 
differentiation to non-dividing, metacyclic promastigotes that can be transmitted when the 
sandfly takes another blood meal. Figure and legend reprinted with permission from Nature 
Publishing Group: Nature Reviews Immunology, Sacks, D. and Noben-Trauth, N. 2(11):845-
858, copyright 2002. 
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Figure 2 The ERK/MAPK pathway. Most cell-surface receptors activate Ras GTPases. 
Ras GTPases comprise a large family of mostly membrane-resident proteins that shuttle 
between an inactive GDP-bound and active GTP-bound conformation. The best-
characterized family members are K-Ras, H-Ras and N-Ras, which are encoded by potent 
proto-oncogenes that are mutated in 30% of human tumours. The oncogenic mutations 
prevent them from hydrolysing GTP, which maintains them in the activated state. In its 
activated conformation, Ras GTP can bind to a number of effector molecules, including the 
serine/threonine kinase Raf, phosphatidylinositol 3-kinase, RalGDS and others. Ras GTP 
recruits these proteins to the membrane compartment, which is crucial for their activation 
and signaling function. All three Raf family members, A-Raf, B-Raf and Raf-1, bind Ras
GTP as the first step in their activation process. Whereas Ras GTP association might 
suffice to activate B-Raf, both Raf-1 and A-Raf undergo a complex series of activation steps 
that have not been entirely elucidated and involve changes in phosphorylation levels and 
protein interactions. All Raf isoforms can activate MAPK and ERK kinase (MEK) by 
phosphorylating two serines in the MEK activation loop, although B-Raf is much more 
effective at doing so than Raf-1, which is better than A-Raf. The gene that encodes B-Raf is 
also mutated in many cancers, mainly in melanoma and cancers of the thyroid, colon and 
ovaries. MEK is a dual-specificity kinase, the only known substrate of which is extracellular 
signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK), the prototypical 
MAPK that is activated by phosphorylation of both the threonine and tyrosine residues in a 
TEY motif that is in the activation loop. Both MEK and ERK/MAPK have two isoforms in 
mammals, which, in most instances, are co-regulated but might have different functions. 
ERK/MAPK is considered the main effector of this pathway and has more than 70 known 
substrates that include nuclear transcription factors, cytoskeletal proteins, signaling proteins 
and receptors. Figure and legend reprinted with permission from Nature Publishing Group: 
Nature Reviews Molecular Cell Biology, Kolch, W., 6(11):827-837, copyright 2005. 
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Figure 3 Scaffold proteins KSR1, MP1, and MORG1. MEK partner-1 (MP1) is a scaffold 
that coordinates the interaction between extracellular signal-regulated kinase/mitogen-
activated protein kinase (ERK/MAPK) and MAPK and ERK kinase (MEK). The MP1–MEK–
ERK/MAPK complex is targeted to late endosomes by p14. MP1 also binds to MAPK 
organizer-1 (MORG1). The exact composition and localization of MORG1 complexes are 
unknown. MORG1 also binds Raf-1 in addition to MP1, MEK and ERK/MAPK, and co-
localizes with vesicles in cells. The MORG1-bound ERK/MAPK complex is selectively 
stimulated by serum and lysophosphatidic acid (LPA), which are agents that function mainly 
through G-protein-coupled receptors (GPCRs), but not through epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF), which signal through receptor tyrosine 
kinases (RTKs). By contrast, ERK/MAPK complexes that are coordinated by the scaffold 
MP1–p14 on endosomes in the absence of MORG1 or by KSR1 at the cell membrane 
respond to both GPCR and RTK signals. Figure and legend reprinted with permission from 
Nature Publishing Group: Nature Reviews Molecular Cell Biology, Kolch, W., 6(11):827-837, 
copyright 2005. 
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CHAPTER 2: IMMUNOLOGIC INDICATORS OF CLINICAL PROGRESSION 
DURING CANINE LEISHMANIA INFANTUM INFECTION 
 
A paper published in Clinical and Vaccine Immunology1 
 
Paola M. Boggiatto2,3,4, Amanda E. Ramer-Tait5, Kyle Metz3,6, Erin E. Kramer3, Katherine 
Gibson-Corley3, Kathleen Mullin7, Jesse M. Hostetter3, Jack M. Gallup3, Douglas E. Jones2,3, 
Christine A. Petersen2,3,8 
 
Abstract 
In both dogs and humans Leishmania infantum infection is more prevalent than 
disease, as infection often does not equate with clinical disease. Previous studies additively 
indicate that advanced clinical visceral leishmaniasis (VL) is characterized by increased 
production of anti-Leishmania antibodies, Leishmania-specific lymphoproliferative 
unresponsiveness, and decreased production of IFN-γ with concomitant increase of IL-10. In 
order to differentiate infection vs. progressive disease for better disease prognostication, we 
temporally evaluated humoral and cellular immunologic parameters of naturally infected 
dogs. The work presented here describes for the first time the temporal immune response to 
natural autochthonous L. infantum infection in Foxhounds within the United States.  Several 
key changes in immunological parameters should be considered to differentiate infection 
versus clinical disease, including a dramatic rise in IgG production, progressive increases in 
antigen-specific PBMC proliferation, and IFN-γ production. Polysymptomatic disease is  
precluded by increased IL-10 production and consistent detection of parasite kinetoplast 
DNA in whole blood. This clinical presentation and immuno-dysregulation mirrors that 
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observed in human patients indicating that this animal model will be very useful for testing 
immunomodulatory anti-IL-10 or other therapies. 
 
Introduction 
Leishmaniasis is a group of vector-borne diseases caused by intracellular protozoan 
parasites of the genus Leishmania. Disease manifestation can range from localized, self-
healing cutaneous ulcers to disseminated disease, referred to as visceral leishmaniasis 
(VL). VL is fatal if left untreated. It is primarily caused by Leishmania (L.) donovani in Africa 
and India, and by L. infantum/chagasi in the Mediterranean basin, Asia and Central and 
South America.  
VL, as caused by L. infantum infection, is zoonotic (4). Both dogs and humans are 
natural hosts (27), and in endemic regions, infected dogs are the primary domestic reservoir 
for zoonotic VL and the most significant risk factor predisposing humans to infection (9). L. 
infantum infection often does not equate with clinical disease (18). Typical clinical signs of 
VL include fever, weight loss, anemia, lymphadenopathy, and hepato- and splegnomegaly 
(4, 22, 27).Clinical stages of infection can be classified by the severity of clinical signs, 
humoral and cell-mediated responses, and parasite load (33). We propose that these 
parameters can also be used to determine the best window for treatment and in some cases 
predict the appearance of clinical signs and prognosis (24). 
Host protection against Leishmania infection requires a proinflammatory, TH1 
immune response, as characterized by the production of interleukin (IL)-12 by antigen 
presenting cells and interferon (IFN)-γ by T cells (reviewed in (22)).  Advanced clinical VL in 
human patients is characterized by Leishmania-specific lymphoproliferative 
unresponsiveness and decreased production of IFN-γ following in vitro Leishmania antigen 
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restimulation (11, 31). Active disease is associated with elevated IL-10 levels in serum and 
enhanced IL-10 mRNA in lesional tissues (reviewed in (22)). Cured or subclinical individuals 
are able to mount antigen-specific IFN-γ responses following Leishmania antigen 
restimulation in vitro. Cured patients are also resistant to reinfection and are leishmanin skin 
test positive, suggesting no inherent defect in the antigen-dependent TH1 response (3, 7, 
34).  
Canine visceral leishmaniasis (CVL) in endemic areas mimics both the immunologic 
alterations and pathophysiology of human disease. Autochthonous L. infantum infection in 
the United States Foxhound population has been recently described (5, 8). Despite a 
potentially different means of transmission, i.e. non-vector borne (12, 24, 29), symptomatic 
disease and pathologic findings in naturally infected Foxhounds parallels that observed in 
both canines and humans endemic regions (12). For these studies, we hypothesized that 
the immunopathology of primarily non-vector mediated L. infantum CVL would reflect the 
changes observed in humans, including increased anti-Leishmania antibodies in sera, and 
decreased lymphoproliferative IFN-γ-mediated responses with increased IL-10 production.  
Here we follow a cohort of U.S. born, naturally-infected canines to determine their 
immunopathology and clinical presentation(s) of autochthonous L. infantum infection. 
Analysis of clinical signs, serology, and kinetoplast-specific qPCR categorized these animals 
into four different groups: 1) non-infected, 2) infected-resistant, 3) infected-susceptible and 
4) clinical, as previously described in (33).  Animals in the 4th clinical state had increased 
production of IgG1 and IgG2, decreased lymphoproliferative responses and IFN-γ 
production, and increased IL-10 production. The appearance of any of these immunological 
parameters correlated with disease progression. 
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The work presented here describes for the first time the temporal immune response 
to natural autochthonous L. infantum canine infection in United States. We show that even 
in the likely absence of vector-mediated transmission (32) clinical presentation and immuno-
dysregulation mirrors that observed in endemically-infected dogs and humans (1, 22). The 
ongoing antigen-specific immune response to L. infantum infection wanes as disease 
progresses and production of anti-Leishmania antibodies and IL-10 are key immunologic 
features of disease manifestation and progression. 
 
Materials and Methods 
Description of Animals 
Although VL is not endemic in the United States, canine visceral Leishmaniasis 
(CVL) has recently been described as an epidemic within the Foxhound population in this 
country. The first report of Foxhound CVL epidemic in the U.S. was in 1999 in a foxhound 
kennel in New York (8). By 2005, it was reported that 60 kennels in 22 states and two 
Canadian provinces had L. infantum-seropositive Foxhounds, and that autochthonous 
infection in canines was for the most part limited to Foxhounds (5).  
Dogs used in this study, all Foxhounds, ranged in age from six months to seven 
years of age. These animals or their tissues were donated to Iowa State University College 
of Veterinary Medicine by two different Midwestern Foxhound kennels. Nine of the dogs 
were donated based on positive serological indirect immunofluorescence assay test (IFAT) 
results (>1:64) and presentation of clinical signs. The remaining four dogs were born to an 
IFAT positive (> 1:256) female.  All animals were housed at Iowa State University Veterinary 
College and the Institutional Animal Care and Use Committee at Iowa State approved all 
protocols involving animals. Prior to arrival, all dogs were vaccinated for core canine 
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diseases. Once under the care of laboratory animal resources (LAR) at Iowa State 
University, blood samples were obtained for complete blood count (CBC) and chemistry, 
and stool samples were collected for enteric parasite assessment. All animals were treated 
for ecto- and intestinal parasites (Giardia, roundworms, and Coccidia) via treatment with 
Strongid (5mg/kg), Baytril (¼ tablet), Albon (55mg/kg), Panacur (2ml/kg), Clavamox 
13.75mg/kg, and Cephalexin (25mg/kg).  
 
Clinical Evaluation 
Upon arrival to Iowa State University College of Veterinary Medicine, all animals 
were clinically assessed via physical examination, complete blood count, chemistry panel 
analysis, L. infantum kDNA specific qPCR and IFAT serologic analysis. Based on these 
parameters, animals were classified into four distinct categories: non-infected, showing no 
clinical signs of disease and qPCR and IFAT negative; infected-resistant, showing none to 
mild clinical signs and IFAT and qPCR positive/negative; infected-susceptible, showing mild 
to moderate clinical signs and qPCR and IFAT positive; and clinical, showing severe, 
disseminated disease, and IFAT and qPCR positive.  
 
Parasites 
Leishmania infantum (LIVT-2) (30) was grown to stationary phase in complete 
Grace’s medium (Incomplete Grace’s supplemented with 20% fetal bovine serum, 100U/ml 
penicillin, 100ug/ml streptomycin and 2mM L-glutamine). Freeze-thawed whole antigen was 
prepared as described previously (13).  
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Peripheral blood mononuclear cell (PBMC) Isolation and Carboxyfluorescein succinyl ester 
(CFSE) Staining 
All animals were allowed to acclimate for one week prior to immunological studies. 
PBMC were isolated from heparinized blood samples using Ficoll-Histopaque 1077 (Sigma, 
St. Louis, MO) gradient centrifugation. Red blood cells were removed using ACK lysis buffer 
(0.15M NH4Cl, 1.0mM KHCO3, 0.1mM Na2EDTA, pH 7.4). PBMC were labeled with CFSE 
(Molecular Probes, Eugene, OR) as described previously (14). PBMC were washed twice in 
phosphate-buffered saline (PBS) and resuspended in complete medium (RPMI 1640 
supplemented with 10% fetal bovine serum, 100U/ml penicillin, 100ug/ml streptomycin, 2mM 
L-glutamine, and 25mM HEPES buffer). PMBC were counted and adjusted to 4x106/ml for 
further analysis.  
 
PBMC Proliferation Assay 
CFSE-labeled PBMC (4x105/well) were plated on 96-well plates and incubated with 
media alone, stimulated with concavanalin A (ConA) (5ug/ml) for 4 days or with freeze-
thawed, whole L. infantum antigen (10ug/ml) for 7 days, or Distemper vaccine (Vanguard 
Plus 5, Pfizer) control for 10 days, at 37ºC with 5% CO2. Cells were harvested, washed in 
FACS buffer (0.1% albumin, 0.1% sodium azide in PBS) and labeled with PE-conjugated 
anti-canine CD4 antibody (Serotec, Raleigh, NC). Cells were fixed in 1% paraformaldehyde 
and analyzed using the FACSCanto flow cytometer (BD Pharmingen, San Diego, CA). Data 
was analyzed using FlowJo software (Tree Star Inc., Ashland, OR). 
 
IFN-gamma and IL-10 ELISA 
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Unlabeled PMBC (2x105) were plated and incubated as described above. 
Supernatants were collected at the indicated time points and stored at -20ºC until analysis. 
IFN-γ and IL-10 production were measured using R&D ELISA kits (Minneapolis, MN), 
according to manufacturer’s recommendations.  
 
Serology and Real Time qPCR 
Serum samples were collected from all animals, stored at -20ºC and sent to the 
Centers for Disease Control and Prevention for IFAT testing for antibodies to Leishmania 
spp. as previously described (5). DNA from whole blood samples collected in heparinized 
tubes (BD Pharmingen, San Diego, CA) was isolated using the Qiagen blood DNA isolation 
kit according to manufacturer’s instructions. DNA quality and quantity was measured using a 
NanoDrop spectrophotometer ND1000 (Wilmington, DE). L. infantum kinetoplast DNA 
(kDNA)-specific primers and probe  F 5’-CCGCCCGCCTCAAGAC, R 5’-
TGCTGAATATTGGTGGTTTTGG, (Integrated DNA Technologies, Coralville, IA), Probe 5’-
6FAM-AGCCGCGAGGACC-MGBNFQ (Applied Biosystems, Foster City, CA) were used. 
(FAM: laser-activated reporter dye; MGBNFQ: 3’-minor-groove binder non-fluorescent 
quencher).  Blood DNA samples were assayed via qPCR in duplicate of three dilutions 
(straight, 1:10, 1:20) using a Stratagene Mx3005P® qPCR System via a 96-well format and 
Platinum qPCR SuperMix-UDG Master Mix (Invitrogen, Carlsbad, CA). Primers were used at 
775 nM and probe at 150 nM with thermocyling at 50°C for 2 minutes, 95°C for 2 minutes, 
and 50 cycles of [95°C for 30 seconds, 57°C for 1 minute and 60°C for 1 minute]. Results 
were analyzed via MxPro™ QPCR software version 4.01 in conjunction with Microsoft Excel.  
L. infantum-specific IgG ELISA 
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High-affinity plates were coated overnight at 4ºC with 10ug/well of freeze-thawed L. 
infantum antigen in 50mM carbonate-bicarbonate buffer. Plates were blocked with 200ul of 
blocking buffer for 1 hour at room temperature and washed. Serum samples (100ul) were 
diluted 1:100 and incubated for 2 hours at room temperature. Plates were developed with 
HRP-conjugated anti-canine IgG1 or IgG2 (1:20,000) (Bethyl Laboratories, Montgomery, 
TX) for 1 hour and Absorbance was read at 405nm using a microplate reader (Molecular 
Devices, Sunnyvale, CA).     
Statistical analysis 
Statistical significances were analyzed using Prism4 (GraphPad Software Inc., La 
Jolla, CA). Differences between groups were determined using Mann-Whitney U-test.   P-
values below 0.05 were considered significantly different.                                                            
 
Results 
Clinical evaluation 
 Clinical assessment included a complete blood (cell) count (CBC) and chemistry 
panel (Table 1, fourth column). Following euthanasia, necropsy was performed by a 
veterinary pathologist and a complete set of tissues was collected for each animal and 
evaluated histologically (Table 1, last two columns).  Lymphocytosis (elevated lymphocyte 
numbers in the blood) was consistently present in all dogs tested. Persistent lymphocytosis 
is indicative of chronic antigen stimulation, which we would attribute to the presence of 
Leishmania parasites in infected animals. However, since non-infected dogs also show 
lymphocytosis, we cannot rule out the possibility of increased circulating lymphocyte number 
due to other infections including gastrointestinal or ecto-parasitism, which has been 
observed in these Foxhounds previously (data not shown). In all infected animals we 
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observed a moderate to marked hyperglobulinemia. Serum chemistry and histopathologic 
findings in the infected-susceptible dogs indicated the onset of systemic disease consistent 
with visceral leishmaniasis, including elevated blood urea nitrogen (BUN), creatinine and 
phosphorous, anemia, lymphoplasmacytic portal hepatitis, histiocytic splenitis, and 
membranous glomerulonephritis. CBC and serum chemistry evaluation of clinical dogs 
indicated these animals had signs of nonregenerative anemia, renal compromise (elevated 
BUN, creatine and phosphorus), and hepatic injury (elevated alanine transferase). Despite 
their clinical state, lymphocytopenia was not observed in clinical dogs. Histopathologic 
examination confirmed these findings and also showed systemic histiocytic inflammation 
with a myriad of intracellular Leishmania amastigotes.  
 
Serology and qPCR 
To confirm infection and disease status, each dog was evaluated for L. infantum 
serostatus and qPCR for L. infantum kinetoplast (k) DNA. Serum samples from all 
Foxhounds in the study were sent to the Centers for Disease Control and Prevention (CDC) 
for IFAT analysis of antibodies against Leishmania spp (Table 1). All dogs in the control 
(non-infected, non-Foxhound), non-infected group and two dogs from the infected-resistant 
group were seronegative (≤1:16). The two remaining dogs within the infected-resistant group 
had seropositive titers (1:64). Dogs within the infected-susceptible group (3 dogs) had titers 
of 1:256, and dogs within the clinical group (4 dogs) had strong sero-reactivity to Leishmania 
antigen (1:512).         
L. infantum-specific kDNA amplification was observed in all clinical and infected-
susceptible dogs, and in two of the infected-resistant group. As expected, no amplification 
was observed in the non-infected Foxhounds (Table 1) and in the control, non-Foxhound 
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dogs.  These data indicate that increased parasitemia is found during later stages of 
infection.  
 
L. infantum-specific IgG1 and IgG2 production  
Chemistry findings in serum samples from clinical dogs indicated these animals had 
pan-elevation of immunoglobulins (Ig): IgA >500mg/dl, IgG >5000mg/dl, IgM 400mg/dl; 
normal range 20-150 mg/dl; 1000-2000 mg/dl; and 70-270 mg/dl, respectively. 
Hypergammaglobulinemia has been associated with CVL disease progression 
pathophysiology (12) and suppression of the immune response to L. infantum (26). 
However, a relationship between immunoglobulin (Ig) G isotype profile and disease 
resistance versus susceptibility remains to be established. Conflicting reports fail to provide 
a clear role for IgG1 or IgG2 production in disease development (25, 28). Based on our 
findings of detectable circulating parasites as disease progressed, we wanted to determine if 
this observation correlated with detection of specific antibody levels. Using whole parasite 
antigen we found that sera from control and non-infected groups contained minimal IgG1 
and IgG2 antibodies when measured by ELISA, as OD values observed were similar to 
background readings (OD ~0.01). Highest levels of anti-L. infantum IgG1 (Figure 1A) and 
IgG2 (Figure 1B) were produced by the infected susceptible and clinical groups. Overall, IgG 
levels increase as disease progresses, however, we did not observe a direct correlation 
between either IgG isotype and clinical status. Other, non-antibody, effector functions may 
therefore be more predictive of disease progression.  
 
L. infantum-specific PBMC proliferative response  
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 A key immunologic feature of late clinical VL is the inability of PBMC to generate a 
protective, L. infantum-specific immune response (31). This is characterized by the loss of 
the antigen-specific lymphoproliferative response and the loss of IFN-γ production. To 
identify if this lack of antigen-responsiveness as disease progresses occurs in our canine 
cohort, we analyzed the antigen-specific proliferative response of PBMC CD4+ T cells from 
all four groups. Blood samples were collected every four weeks during a period of at least 
three months for each dog. PBMC were isolated from whole blood samples, stained with 
CFSE, and stimulated with concavanalin A (ConA), L. infantum antigen, distemper vaccine 
or left untreated. PMBC were then analyzed for CD4+ T cell proliferation via flow cytometry.  
CD4+ T cells from all dogs proliferated in response to stimulation with ConA, indicating that 
the CD4+ T cell compartment was not mitogenically deficient (Figure 2B). In response to 
distemper vaccine stimulation all groups except for the clinical dogs had a proliferative 
response indicating that although mitogenically competent, clinical dogs were not capable of 
initiating antigen-specific proliferative responses (Figure 2A, B). In response to L. infantum-
antigen stimulation, control (uninfected, non-Foxhound) and non-infected dogs showed a 
minimal level of proliferation in response to antigen restimulation (Figure 2). While a 
significantly greater percentage of CD4+ T cells from infected-resistant dogs proliferated in 
response to antigen restimulation as compared to non-infected dogs, infected-susceptible 
dogs demonstrated the greatest percentage of proliferative CD4+ T cells, significantly higher 
than infected-resistant animals (Figure 2A). In contrast, the antigen-specific CD4+ T cell 
proliferative response from clinical animals was significantly decreased as compared to that 
of infected-susceptible dogs. These data suggest that as disease progresses, there is an 
initial increase in antigen-specific lymphoproliferative responsiveness of CD4+ T cells that 
eventually dwindles. Appearance of clinical disease correlates with the loss of the antigen-
61 
 
 
 
specific lymphoproliferative response. Based on this observed loss of proliferative response 
in late disease, we wished to determine if cytokine production, specifically IFN-γ and IL-10, 
could be correlated with this lympho-suppressive change.   
 
Disease progression and antigen-specific PBMC IFN-γ and IL-10 production  
 Treated individuals develop a cell-mediated immune response capable of offering 
protection from reinfection, as characterized by antigen-specific IFN-γ responses (7, 34). In 
contrast, individuals with advanced VL show a decrease in antigen-specific IFN-γ production 
and elevated levels of the immunoregulatory cytokine IL-10 in serum and increased IL-10 
mRNA expression in lesional tissue (6, 10). The correlation between VL disease progression 
and IL-10 production in humans is now well established (22). In CVL, IFN-γ-mediated 
responses seem to predominate in L. infantum-infected but asymptomatic dogs (23). Similar 
to human disease, IL-10 mRNA expression has been positively correlated with parasitic load 
and progression of clinical disease in naturally infected dogs (15). In order to determine the 
correlation between disease and cytokine production in our cohort, culture supernatants 
from PBMC restimulated with L. infantum antigen were assayed for IFN-γ (Figure 3A) and 
IL-10 (Figure 3B) production. Production of IFN-γ and IL-10 from PBMC in the control group 
(Figure 3A and B) was below the detection limit of the assay (16pg/ml and 10pg/ml 
respectively). PMBC from infected-resistant and infected-susceptible animals produced 
comparable levels of IFN-γ (Figure 3A). PBMC from infected-resistant dogs produced 
significantly higher levels of IFN-γ as compared to non-infected animal PMBC. PBMC from 
clinical dogs, however, produced significantly lower amounts of IFN-γ as compared to 
infected-susceptible and infected-resistant dogs. 
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 Analysis of IL-10 production from culture supernatants indicated a significant 
increase in the production of this cytokine with disease progression. PBMC from dogs in the 
clinical group produced the greatest amount of IL-10 as compared to all other groups 
(Figure 3B), with decreasing amount detected from infected-susceptible and then infected-
resistant dogs. All three groups were significantly different from one another. PBMC from 
non-infected dogs produced levels of IL-10 that were below the detection limit of the assay 
(10pg/ml). These data demonstrate that clinical progression and loss of antigen-specific T 
cell proliferation in our cohort were associated with decreased levels of antigen-specific IFN-
γ production, and increased production of IL-10 in response to L. infantum antigen 
restimulation.  
 
Discussion 
 During CVL, susceptibility to symptomatic infection has been associated with 
increased antibody production and loss of L. infantum-specific CD4+ T cell function with a 
concomitant increase in immunosuppressive mechanisms. However, little is known 
regarding the mechanisms that control the balance between resistance to infection and 
susceptibility. Characterization of measurable immunopathological endpoints may provide a 
means to better predict disease development in infected dogs. Our studies using a cohort of 
naturally infected dogs show how changes in IgG production, lymphoproliferative responses, 
and effector cytokine production correlate with the appearance of clinical signs and disease 
progression.  
 In our study increases in serologic titer were associated with disease progression 
(Table 1). The highest titers (1:256 and 1:512) were observed in dogs displaying mild to 
severe clinical disease within the infected-susceptible and clinical groups. Moreover, high 
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antibody titers also correlated to the detection of L. infantum parasites in peripheral blood 
samples via qPCR (Table 1), indicating an increase in circulating parasites later in disease. 
Analysis of antigen-specific IgG1 and IgG2 in sera of the four groups of dogs showed an 
increase in both isotypes with disease progression (Figure 1A and B).  Infected-susceptible 
and clinical dogs exhibited the highest O.D. values indicating increased IgG1 and IgG2 
levels as compared to non-infected and infected-resistant dogs but there was no clear 
difference between isotypes regarding clinical state or progression. 
 During human VL increased levels of anti-Leishmania IgG have been shown to have 
a negative correlation with delayed-type hypersensitivity (DTH) responses (17). Here we 
show that along with increased IgG in sera, L. infantum-antigen responsiveness of PBMC 
CD4+ T cells significantly decreased in the clinical group of animals (Figure 2). This loss of 
lymphoproliferation has been described as “immune exhaustion” due unchecked levels of 
pathogen antigen (2, 19). Infected-susceptible animals showed the most robust proliferative 
response compared to all other groups. Proliferation in the non-infected Foxhound group 
may be attributed to non-specific proliferation or perhaps a dwindling recall response. 
Animals in this group were donated as part of a litter of puppies born to a seropositive, 
qPCR-positive female. It is therefore possible they may have been exposed to L. infantum 
parasites in utero at a very low dose, leading to exposure and some T cell activation but 
perhaps not patent infection. Altogether, our data shows that PBMC CD4+ T cells from L. 
infantum-infected dogs respond to antigen stimulation during the earlier stages of infection, 
but lose that ability as they progress to clinical disseminated disease, negatively correlating 
with the increased levels of IgG in sera.   
 Antibody production is an important contributor to VL pathology due to antigen-
antibody complex deposition. B cell activation and increased IgG production are observed in 
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conjunction with IL-10 overproduction during VL (22). To determine what effector cytokines 
were produced by the dampened T cells with limited antigen-responsiveness in our cohort, 
we assessed IFN-γ and IL-10 production in cultured PMBC. We found that decreased 
proliferative responses in the clinical group were accompanied by significantly decreased 
IFN-γ production (Figure 3A) and significantly increased IL-10 production (Figure 3B). This 
profile matches observed changes in cytokine production in endemic human cohort studies 
(10, 20, 21, 31) and dogs (23). Our infected-resistant and infected susceptible groups 
produced similar levels of IFN-γ, however, the infected-susceptible group showed 
significantly increased production of IL-10 compared to the infected-susceptible group. The 
observed increase in IL-10 production, along with increased blood parasite burden, may be 
specific factors which promote clinical disease.  
 The factors that determine disease progression in CVL remain poorly understood. It 
is clear that no one clinical parameter can be used to predict which infected dogs will likely 
become clinically ill. Our studies using our canine cohort of progressive CVL indicate that 
several key changes in clinical parameters should be considered, including a rise in IgG 
production, a progressive increase of antigen-specific PBMC proliferation followed by a 
decreased IFN-γ-mediated response, a dramatic increase in IL-10 production, and 
consistent detection of parasite kDNA in whole blood. Further studies are needed to fully 
understand the relationship between increased IgG, IL-10 production and parasite load.  
While it has been shown that all three of these events precede clinical disease (16, 17, 23), 
the causal relationship between them is yet to be determined. Understanding which event 
drives the others may provide insight into the mechanisms leading to VL and provide 
thought for future immuno-therapies.  
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Figure 1. Anti-L. infantum IgG1 and IgG2 responses increase with CVL disease 
progression. L. infantum-specific IgG responses were measured using sera from control (1 
dog, ■), non-infected (2 dogs, □), infected-resistant (4 dogs, ♦), infected susceptible (2 dogs, 
○) and clinical (3 dogs, ●) animals via ELISA. Blood samples were collected and centrifuged 
to clarify serum.  Shown are O.D. values from antigen-specific (A) IgG1 and (B) IgG2 ELISA. 
Lines indicate mean value for each group.  
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Figure 2. Decreased lymphoproliferative response in PBMC from L. infantum-infected, 
clinical dogs. (A)  PBMC proliferative responses from control (1 dog, ■), non-infected (2 
dogs, □), infected-resistant (4 dogs, ♦), infected susceptible (2 dogs, ○) and clinical (2 dogs, 
●) animals repeated monthly over three to six months. PBMC were isolated, stained with 
CFSE, restimulated with freeze-thawed L. infantum antigen, and incubated for seven days at 
37ºC. Cells were then harvested and stained with a PE-conjugated anti-CD4 antibody. 
PMBC CD4+ T cell proliferation was assessed via CFSE dilution using flow cytometry. Each 
point is indicative of a blood draw from each animal over a three to six month period and 
subsequent proliferation assay. At least four separate proliferation assays were carried out 
over time on each dog in every group. Lines indicate the mean response for each group. (*) 
Indicates significant difference, p< 0.05. (B) PBMC proliferative response to L. infantum 
(black), Distemper vaccine (DHPP) (gray), and ConA (white) stimulation for control (1 dog), 
infected-susceptible (3 dogs) and clinical dog (2). PBMC were isolated and processed as in 
(A) and stimulated with L. infantum Ag for seven days, DHPP for 10 days and ConA for 4 
days. CD4+ T cell proliferation was assessed via CFSE dilution using flow cytometry. At 
least 3 separate experiments were carried out for each dog in every group. Bars indicate 
average proliferation for each group, ±SEM. 
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Figure 3. Disease progression correlates with decreased IFN-γ and increased IL-10 
production. Shown are PBMC effector cytokine responses from control (1 dog, ■), non-
infected (2 dogs, □), infected-resistant (4 dogs, ♦), infected susceptible (2 dogs, ○) and 
clinical (2 dogs, ●) animals. Culture supernatants were collected from PBMC cultures 
stimulated with L. infantum antigen for seven days and analyzed via ELISA for (A) IFN-γ and 
(B) IL-10. Each point is indicative of one experiment. At least three separate experiments 
were carried out for each dog in every group. Lines indicate the mean response for each 
group. (*) Indicates significant difference, p< 0.05. 
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Abstract 
Dendritic cells (DC) are professional antigen presenting cells, critical for induction 
and regulation of T cell immune responses against pathogens, including Leishmania. 
Leishmania, intracellular protozoan parasites, are the causative agent for a group of 
diseases that range from benign to fatal. Initiation of productive immune responses against 
this pathogen depends on the successful transition of DC from an immature to a mature 
phenotype, characterized by high CD40 surface expression and IL-12 production. This 
productive immune response is frequently seen in response to L. major infection.  
Characterization of draining lymph node CD11c+ DC from L. amazonensis or L. major 
promastigote-infected mice revealed that by 7 days post-infection, CD11c+ cells from the 
draining lymph node of L. amazonensis promastigote-infected mice have significantly 
reduced CD40 surface expression.   At 7 days post-infection the number of IL-12p40-
producing cells is drastically decreased as compared to DC from L. major-infected mice.  
Analysis of MAP kinase signaling revealed that infection of DC in vitro with L. amazonensis 
resulted in increased ERK phosphorylation. Inhibition of ERK in vitro or in vivo led to 
enhanced DC surface CD40 expression and in vitro increased IL-12p40 production. In 
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conclusion, Leishmania amazonensis amastigote-mediated regulation of DC maturation 
occurred via increased phosphorylation of the MAP kinase ERK.  
 
Introduction 
Leishmaniasis is a vector-borne disease caused by intracellular protozoan parasites 
of the genus Leishmania. The intracellular amastigote stage of Leishmania predominates in 
the mammalian host while the vector stage exists as an extracellular, flagellated 
promastigote. Both promastigotes and amastigotes are capable of initiating mammalian 
infection. Leishmania amastigotes have been shown to interfere with host cell function, 
including modulation of signaling pathways, suppression of antimicrobial and pro-
inflammatory mediators, and induction of cytokines that promote disease progression.1, 2 
Infection of C3HeB/FeJ mice with Leishmania major leads to the development of a 
healing TH1 immune response characterized by high levels of interleukin-12 and interferon 
(IFN)-γ-producing CD4+ T cells.3 In contrast, infection with L. amazonensis results in a non-
healing immune response, leading to chronic disease and high parasite loads. Multiple 
studies have investigated and identified differences in the T cell response to these two 
parasites.4-6 Studies from our laboratory have revealed that antigen-responsive CD4+ T cells 
from C3HeB/FeJ mice chronically infected with L. amazonensis are impaired in their ability 
to transition from a naïve to an effector phenotype.6  
 
Leishmania spp. infect phagocytic cells of the immune system, primarily 
macrophages and dendritic cells (DC). DC are antigen presenting cells (APC) which 
efficiently initiate antigen-specific immune responses by inducing the differentiation of naïve 
T cells.7 DC maturation can be characterized in vitro and ex vivo by the upregulation of co-
stimulatory molecules including CD40 and the production of T cell-polarizing cytokines such 
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as interleukin (IL)-12.7  Clearance and resistance to Leishmania infection is dependent on 
the development of a TH1 response3, 8 and susceptibility to Leishmania infection has been 
associated with deficiencies in CD40, CD40 ligand,9-11 and IL-12 or IL-12 receptor 
subunits.12, 13 Infection of C57BL/6 mice bone marrow-derived dendritic cells (BMDC) with L. 
amazonensis promastigotes indicated a significant reduction in CD40 surface expression 
and IL-12p40 production as compared to L. major promastigote-infected BMDC.14  
Moreover, a recent publication indicated that L. amazonensis amastigote infection of BMDC 
significantly down-regulated CD40 expression and suppressed IL-12p40 and IL-12p70 
production, leading to an impairment in APC function, characterized by an inability of L. 
amazonensis-amastigote infected BMDC to prime naïve CD4+ T cells or re-stimulate 
antigen-specific CD4+ T cells.15  
Improper or insufficient activation of dendritic cells (DC) can promote a non-
polarized, often tolerogenic, T cell response. DC maturation depends on the balance of 
particular molecular signaling cascades.7, 16, 17 One such pathway is mitogen activated 
protein kinase (MAPK) signaling cascades composed of three primary kinases, p38, c-Jun 
N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK).  A recent report 
has linked ERK activation in macrophages with the induction of IL-10, a critical cytokine 
involved in host susceptibility to Leishmania infection.18 Work from our own laboratory has 
shown that inhibition of ERK in vitro increases the ability of L. amazonensis-infected 
macrophages to kill the intracellular parasites.19 Unlike p38 and JNK, ERK has been shown 
to play a role in preventing proper maturation of DC.16, 20 
As L. amazonensis-infected mice fail to develop an effective TH1 response,4-6 and L. 
amazonensis-infected BMDC in vitro have been shown to have an altered maturation 
phenotype,14, 15 we hypothesized that L. amazonensis infection in vitro promotes an 
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immature DC phenotype consistent with the observed lack in T cell polarization. In this 
study, we present novel ex vivo evidence that L. amazonensis infection promotes an 
immature CD11c+ DC phenotype characterized by significantly low CD40 surface expression 
and significantly decreased IL-12p40 production as compared to L. major infection. 
Furthermore, we explored the molecular mechanisms that may lead to impaired DC 
maturation and found that in vitro, BMDC infection with L. amazonensis amastigotes 
resulted in rapid and significant phosphorylation of the MAP kinase ERK1/2, observed within 
minutes of exposure to the parasite. Infection with L. amazonensis promastigotes led to 
increased ERK1/2 phosphorylation as compared to L. major infection; however, this 
phosphorylation was delayed several hours. This delay in phosphorylation correlated with 
promastigote transformation into amastigotes within infected DC, as confirmed by 
microscopic analysis of parasite stage prior to and after initiation of robust ERK 
phosphorylation. In vitro inhibition studies determined that treatment of DC with a MEK-
specific inhibitor, PD98059, led to enhanced surface CD40 expression and IL-12p40 
production following L. amazonensis-amastigote infection as compared to non-treated cells. 
Treatment of L. amazonensis-infected mice with the highly-specific MEK inhibitor, CI-1040, 
enhanced surface CD40 expression. Together, this data indicates that L. amazonensis 
amastigotes, through activation of the MAP kinase ERK1/2, inhibit the ability of DC to 
undergo proper maturation in vivo. This is the first report of use of a biochemical inhibitor, 
here targeted to the MAPK ERK, which restores the immune phenotype of dendritic cells 
after pathogen infection both in vitro and in vivo.  
 
Materials and Methods 
Mice  
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C3HeB/FeJ mice were bred in house or obtained from Jackson Laboratories (Bar 
Harbor, ME) and maintained in a specific-pathogen-free facility. The IACUC at Iowa State 
University approved all protocols involving animals. Six- to eight-week old females were 
inoculated with 1 x 106 stationary-phase promastigotes in 50 μl of phosphate-buffered saline 
(PBS) in the left hind footpad.  
C3H severe combined immunodeficiency (SCID) mice (C3SnSmn.CB17-Prkdcscid/J) 
were inoculated with 1-2 x 107 stationary-phase promastigotes in 50 μl of PBS in the left 
hind footpad. These mice were later sacrificed for tissue-derived amastigotes.  
For in vivo ERK inhibitor treatment, L. amazonensis- and L. major-infected 
C3HeB/FeJ mice were orally gavaged twice daily with 100mg/kg of CI-1040 (kind gift from 
Pfizer Global Health, Groton, CT) in dimethyl sulfoxide (DMSO) supplemented with 0.5% 
hydroxypropyl methyl cellulose (HPMC) and 0.2% Tween 80, for a total of 7 days and 
sacrificed.  
 
Isolation and preparation of bone marrow-derived dendritic cells (BMDC) 
BMDC were cultured in vitro in the presence of 10 ng/ml of murine granulocyte-
macrophage colony-stimulating factor (PeproTech Inc., Rocky Hill, NJ) according to the 
method of Lutz et al.21 At day 10 of culture, approximately 90% of the BMDC were positive 
for the DC marker CD11c. For in vitro studies, 10-day-old BMDC were incubated for 24 h at 
37°C, 5% CO2 with fresh, tissue-derived amastigotes at a cell to parasite ratio of 1:3.  
 
Parasites and infection 
Culture of L. amazonensis (MHOM/BR/00/LTB0016) and L. major 
(MHOM/IL/80/Friedlin) parasites was performed as previously described.5 For in vitro 
79 
 
 
 
promastigote experiments, stationary phase L. amazonensis or L. major promastigotes were 
used. Where indicated, parasites were labeled using the dye carboxyfluorescein diacetate 
succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR) as previously described22 with 
some modifications. Amastigotes were directly recovered from footpad lesions of infected 
C3H SCID mice. Infected feet were disinfected with 70% ethanol, and extraneous tissue 
dissected away. The remaining lesion was then homogenized with a Tenbrock tissue 
homogenizer. Cellular debris was removed by centrifuging at 180 x g for 15 min at 4ºC. The 
resulting supernatant was centrifuged at 3000 x g for 15 min at 4ºC. The number of viable 
amastigotes in the pellet was assessed by fluorescent microscopy with fluorescein diacetate 
(Acros Organics, Morris Plains, NJ) and propidium iodide (Sigma, St. Louis, MO). For in vitro 
infection of BMDC, cells were infected with either L. amazonensis or L. major at a multiplicity 
of infection (MOI) of 3. Where indicated, as a positive control for maturation, some BMDC 
were stimulated with 500ng of LPS (Sigma, St. Louis, MO) and 200iU of IFN-γ (Pharmigen, 
San Diego, CA), or treated with the MEK inhibitor PD98059 (Sigma, St. Louis, MO).  
 
Flow cytometry 
For flow cytometry analysis of surface molecule expression, 1 x 106 BMDC were 
washed in 2 ml of FACS buffer (0.1% sodium azide and 0.1% BSA in phosphate buffer 
saline). Fcγ receptors were blocked with 10% purified rat anti-mouse CD16/CD32 antibody 
(BD Pharmingen, San Diego, CA) in 1mg/ml rat IgG for 20 min at 4ºC to prevent nonspecific 
binding. BMDC were then incubated with the appropriate antibody or isotype control for 30 
min on ice. The antibodies used include FITC-labeled CD11c (HL3), PerCP-Cy5.5-labeled 
CD11b (M1/70), PE-labeled CD40 (3/23), APC-labeled CD80 (16-10A1), PE-Cy7-labeled 
CD86 (GL-1), APC-Cy7-labeled CD19 (1D3), and APC-Cy7-labeled CD3e (145-2C11). 
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CD11c, CD11b, CD40, CD19 and CD3 were purchased from BD Pharmigen (San Diego, 
CA). CD80 and CD86 were purchased from Biolegend (San Diego, CA). Following staining, 
cells were washed in 2ml of FACS buffer and fixed in 200ul of 1% paraformaldehyde and 
stored at 4ºC until analysis. Analysis was performed on a BD FACScanto flow cytometer 
(Becton Dickinson, San Jose, CA), and data analyzed using FlowJo software V8.5.2 (Tree 
Star, Inc., Ashland, OR).  
 
Isolation of cell extracts 
To make whole cell lysates, 3 x 106 BMDC were resuspended in 400 μl of 1x cell 
lysis buffer (Cell Signaling Technologies, Beverly, MA), supplemented with 1mM 
phenylmethylsulphonyl fluoride (PMSF) and a protease inhibitor cocktail (Roche, 
Indianapolis, IN) immediately prior to use. Samples were incubated on ice for 15 min and 
then centrifuged at 16,000 x g for 5 min at 4ºC. Supernantants were collected as whole cell 
lysates and stored at -80ºC.  
 
Immunoblot analysis 
Protein content of all cell extracts was determined via BCA protein assay (Pierce, 
Rockford, IL) according to manufacturer’s recommendations, and all samples were 
normalized to 1mg/ml using distilled water. Samples (20-30 μg of protein) were heated for 4 
min at 95°C in 1x loading buffer and electrophoresis was performed on a 12% sodium 
dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) gel. Gels were 
electroblotted onto polyvinylidene fluoride membranes (PVDF), blocked with 5% bovine 
serum albumin, and probed with antibodies specific for phospho-ERK, p38 and JNK, total-
ERK1/2, p38, JNK (1:1000) (Cell Signaling, Beverly, MA) and β-actin (1:5,000) (Sigma, St. 
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Louis, MO). Signals were detected with horseradish-peroxidase (HRP)-conjugated goat anti 
rabbit antibodies (1:20,000) (Jackson ImmunoResearch, West Grove, PA) using the 
SuperSignal West chemiluminescent substrate (Pierce, Rockford, IL) and expressed to 
autoradiography film (Midsci, St. Louis, MO). 
 
Indirect Immunofluorescence and hematoxylin and eosin stain 
 5x105 BMDC were plated onto 24-well plates containing tissue cover slips. BMDC 
were infected with L. amazonensis promastigotes at an MOI of 3:1 and incubated at 34ºC 
with 5% CO2. Tissue cover slips were then harvested and fixed with 4% paraformaldehyde 
in phosphate buffered saline (PBS) for 20 minutes at room temperature and washed three 
times with PBS. BMDC were permeabilized with 0.1% saponin in PBS for 10 minutes at 
room temperature. Cells were then incubated for 1 hour at room temperature with mouse 
anti-LPG C7AE monoclonal antibody (A kind gift from Dr. Jeffery Beetham) at a 1:100 
dilution in 0.1% saponin. After incubation, cover slips were washed three times with PBS 
and incubated for 1 hour at room temperature with donkey anti-mouse Cy2-conjugated 
antibody (A kind gift from Dr. Bryan Bellaire) (Jackson ImmunoResearch Laboratories, West 
Grove, PA) at a 1:200 dilution in 0.1% saponin. BMDC were then counter stained with 
propidium iodide according to manufacturer’s instructions (Molecular Probes, Eugene, OR). 
Cover slips were then mounted onto slides using MOWIOL (Calbiochem, La Jolla, CA) and 
viewed using an Olympus IX71 inverted epifluorescence scope (Olympus America Inc., 
Center Valley, PA).  
 For morphological analysis, cover slips were harvested at the indicated time points, 
fixed in 100% methanol for 5 minutes and stained with hematoxylin and eosin stain (H&E) 
according to manufacturer’s instructions (Fisher Diagnostics, Middletown, VA). Cover slips 
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were analyzed using a Nikon Eclipse 50i light microscope (Nikon Instruments Inc., Melville, 
NY). 
 
IL-12p40 ELISA and ELIspot 
Supernatants from BMDC cultures were harvested at indicated time points following 
amastigote or promastigote infection, and IL12-p40 ELISA was performed using 
commercially available antibodies (BD Pharmigen, San Diego, CA), peroxidase-conjugated 
streptavidin (Jackson ImmunoResearch Laboratories, West Grove, PA) and ABTS microwell 
peroxidase substrate (Roche, Indianapolis, IN). IL-12p40 ELIspots were performed on total 
lymph node cells using commercially available purified IL-12p40 and biotinylated anti-
IL12p40 antibodies (BD Pharmigen, San Diego, CA), and developed using 2-amino-2-
methyl-1-propanol (2A2M1P) (ICN Biomedicals Inc., Aurora, OH) and 5-bromo-4-chloro-3-
indoly-phosphate (BCIP) (Fisher, Fair Lawn, NJ).  
 
Statistics 
 Statistical analysis between two values was determined via Student’s t-tests. P 
values of < 0.05 were considered as statistically significant.  
 
Results 
Dendritic cells in the draining lymph node of L. amazonensis-infected mice have an 
immature phenotype  
Recent studies demonstrated that BMDC infected with L. amazonensis amastigotes 
have an immature phenotype, as determined by CD40 expression and IL-12p40 and IL-
12p70 production, and are impaired in their ability to prime naïve CD4+ T cells as compared 
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to L. amazonensis promastigote-infected BMDC.15 Our laboratory has shown that CD4+ T 
cells from mice chronically infected with L. amazonensis are impaired in their ability to 
transition into an effector phenotype.6  We propose that these differences in BMDC 
phenotype previously observed to be elicited by L. amazonensis promastigotes and 
amastigotes in vitro, would be reflected during in vivo infection as the infection progresses 
from peracute (2 days post infection (dpi)) to acute (7 dpi). Mice were infected 
subcutaneously in the left footpad with L. amazonensis or L. major promastigotes and 
sacrificed at 2 and 7 dpi. DC, as designated by CD11c+ cells 23 from the draining lymph node 
(DLN) of infected mice, collected based on a CD19 and CD3 double negative events (Fig. 
1A), were analyzed for DC maturation markers. As shown previously, infection with 
Leishmania not only increases the number of CD11c+-events in the draining lymph node, but 
also increases CD40 expression in these cells.23 CD11c+ DC surface expression of CD40 
(Fig. 1B and D), CD80 and CD86 (data not shown) was similar between L. amazonensis- 
and L. major-infected mice at 2 dpi. By 7 dpi, CD11c+ DC from L. amazonensis-infected 
mice had significantly lower CD40 surface expression as measured by FACS analysis as 
compared to DC from L. major-infected mice (Fig 1C and E). No differences were observed 
in the surface expression of CD80 and CD86 (data not shown) between L. amazonensis- 
and L. major-infected mice at 7 dpi, suggesting that CD40 expression is specifically targeted 
for down regulation. 
The number of DLN cells producing IL-12p40 ex vivo was analyzed at 2 and 7 dpi via 
ELIspot. At two 2 dpi, no significant differences were observed in IL-12p40 production from 
the DLN of L. amazonensis- or L. major-infected mice (Fig. 1F). However, by 7 dpi the 
number of IL-12p40-producing cells was significantly decreased in response to L. 
amazonensis infection compared to L. major-infected mice (Fig. 1G). These data suggest 
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that early during infection, L. amazonensis and L. major promastigotes elicit similar DC 
phenotypes in the DLN, as measured by CD40 surface expression and IL-12p40 production. 
However, once the in vivo infection transitions to the acute stage (7 dpi) when the 
amastigote form of the parasite predominates,28 we observe a DC phenotype with 
significantly decreased CD40 surface expression and IL-12p40 production suggesting that 
L. amazonensis amastigotes can modulate the maturation phenotype of DC in vivo as it has 
been observed in vitro. 
 
Increased ERK phosphorylation following infection with L. amazonensis amastigotes 
In order to determine a potential mechanism by which L. amazonensis could inhibit 
CD40 surface expression and IL-12 production during DC maturation, we determined which 
of several signaling pathways are differentially upregulated in DC following infection with L. 
amazonensis and not with L. major infection.  Several reports indicate that activation of 
mitogen-activated protein kinase ERK can prevent proper DC maturation.16, 20 Recent 
published work from our laboratory and others has shown that activation of ERK1/2 
following infection with L. amazonensis amastigotes leads to decreased ability of mouse 
macrophages to kill these intracellular parasites in vitro,19 and promotes a non-healing 
response in infected Balb/c mice.18 Based on these findings, we were interested in 
determining whether ERK phosphorylation occurs in C3HeB/FeJ-derived BMDC after 
infection with either L. amazonensis amastigotes or promastigotes. BMDC infected with L. 
amazonensis amastigotes (Fig. 2A) or promastigotes (Fig. 2B and C) at a 3:1 parasite-cell 
ratio were lysed at the indicated time points and analyzed via western blot for 
phosphorylated ERK1/2. Following L. amazonensis amastigote infection, a significant 
increase in ERK1/2 phosphorylation was observed within minutes of exposure to the 
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parasite (Fig. 2A), compared to L. major amastigote infection. In contrast,  L. amazonensis 
promastigote infection did not result in significantly increased phosphorylated ERK1/2 until 
at least 3 hours post infection (Fig 2B and C) as compared to L. major promastigote-infected 
BMDC. Phosphorylation of ERK1/2 after L. amazonensis amastigote infection was unique to 
ERK1/2 as other MAP kinases, p38 and JNK, were not upregulated following infection (Fig. 
2D and E). 
We hypothesized that the observed delay in ERK1/2 phosphorylation following L. 
amazonensis promastigote infection may correlate with transformation of the parasite into 
the amastigote stage. We analyzed L. amazonensis-infected BMDC at 2 and 4 hours post-
infection to determine which parasite form, promastigote or amastigote, predominated at 
these time points in infected cells. Using both immunofluorescence with an anti-LPG 
antibody (Fig. 3A) and morphology analysis via hematoxylin and eosin stain (H&E) (Fig.3B), 
we show that by 4 hours post-infection the percentage of promastigotes significantly 
decreases correlating with the rise of increased ERK1/2 phosphorylation after promastigote 
infection. These data suggest that L. amazonensis amastigotes specifically induce ERK1/2 
phosphorylation.  
 
ERK inhibition restores CD40 surface expression both in vitro and in vivo following L. 
amazonensis infection 
We have shown that MAPK ERK1/2 is selectively and rapidly phosphorylated 
following L. amazonensis amastigote infection of BMDC.  To examine if increased ERK1/2 
phosphorylation affects BMDC maturation in response to activating stimuli following 
Leishmania infection, BMDC were pre-treated with the specific MEK inhibitor PD98059 and 
then infected with either L. amazonensis or L. major amastigotes and activated with LPS 
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and IFN-γ two hours post-infection.  Following overnight culture, BMDC were analyzed for 
CD40 surface expression via FACS and resultant culture supernatants were analyzed to 
determine IL-12p40 production via ELISA. ERK inhibition of L. amazonensis amastigote-
infected BMDC significantly increased CD40 surface expression MFI (Fig. 4A) and IL-12p40 
production (Fig. 4B) as compared to non-treated L. amazonensis amastigote-infected 
BMDC. Treatment with PD98059 had no effect on the ability of L. major-infected BMDC to 
express surface CD40 as measured by FACS analysis or to produce IL-12p40 (data not 
shown).  
 Based on these in vitro findings, where inhibition of ERK prior to L. amazonensis 
amastigote infection of BMDC enhanced CD40 expression and IL-12p40 production, we 
sought to determine the effect of ERK inhibition in vivo using a different ERK inhibitor, CI-
1040 (100mg/kg). Mice were inoculated in the left footpad with stationary phase L. 
amazonensis or L. major promastigotes. Starting day 0 mice were treated with CI-1040 via 
oral gavage. Twice daily treatment continued for a total of 7 days. Mice were sacrificed one 
week after infection, DLN harvested and CD11c+ DC phenotypes analyzed via FACS as 
described previously (Fig. 1). ERK inhibitor treatment of L. amazonensis-infected mice 
resulted in increased CD11c+ DC surface expression of CD40 (Fig. 4C (left panel) and D) as 
determined by FACS analysis. ERK inhibitor treatment significantly decreased the number of 
IL-12p40-producing cells as measured by ELIspot (Fig. 4F). CI-1040 treatment of L. major-
infected mice had no effect on CD40 surface expression of CD11c+ DC (Fig. 4C (right panel) 
and E) or on the number of IL-12p40 producing cells from the DLN of infected mice (Fig. 
4G).  Western blot analysis of splenic lysates showed that ERK1/2 phosphorylation was 
inhibited in CI-1040-treated animals (Fig. 4H). These data indicate that in vitro L. 
amazonensis infection modulates DC maturation via ERK-mediated down regulation of 
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CD40 surface expression and decreased IL-12p40 production, and that in vivo, ERK 
activation down regulates CD40 surface expression of CD11c+ DC.   
 
Discussion 
 Here we describe a novel L. amazonensis amastigote-dependent mechanism 
modulating DC maturation via activation of the MAP kinase ERK and for the first time 
recover DC phenotype by inhibiting ERK phosphorylation. Alteration of surface marker 
expression, cytokine production, maturation and function of DC following L. amazonensis 
infection has been previously characterized in vitro.15, 24 Defects in DC maturation may, in 
part, contribute to the un-polarized T cell phenotype observed during L. amazonensis 
infection,6 and lead to a non-healing immune response. As early as 7 dpi CD11c+ DLN cells 
from L. amazonensis-infected C3HeB/FeJ mice have significantly reduced CD40 surface 
expression and a decreased number of IL-12p40-producing cells, as compared to L. major-
infected mice. Consistent with another report indicating the activation of the MAP kinase 
ERK during L. amazonensis infection,18 we found that L. amazonensis amastigote infection 
of DC leads to phosphorylation of the MAP kinase ERK1/2. When ERK phosphorylation was 
inhibited, DC surface expression of CD40 increased both in vitro and in vivo, and production 
of IL-12p40 was enhanced in vitro.  
Several pathways that alter DC maturation have been characterized, including MAP 
kinase pathways.16, 20 p38 and JNK phosphorylation were not different between L. 
amazonensis- and L. major-infected BMDC (Fig. 2D and E). ERK1/2 phosphorylation in 
BMDC increased 4-fold within minutes of contact with L. amazonensis amastigotes 
compared to L. major amastigotes (Fig 2A).  ERK1/2 phosphorylation was also observed 
after L. amazonensis promastigote infection of BMDC but not until 3-4 hours post infection 
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(Fig. 2C). Early ERK1/2 phosphorylation observed with in vitro following L. amazonensis 
amastigote infection of BMDC (Fig. 2A) and microscopic analysis revealing that the 
amastigote form of L. amazonensis predominates within infected BMDC by 4 hours post 
infection (Fig. 3), suggest a correlation between ERK1/2 phosphorylation and amastigote 
predominance. We postulate that the amastigote form of L. amazonensis activates the 
ERK1/2 pathway.  
ERK1/2 has multiple cytosolic and nuclear targets.32, 33 The role of ERK1/2 in cellular 
function ranges from cell survival and cell cycle regulation, to modulation of additional 
signaling pathways and regulation of transcription. Both CD40 and IL-12p40 transcription 
can be negatively regulated by activation of ERK1/2.20 ERK1/2 has also been demonstrated 
to play a role in the DC survival rather than maturation.16 Moreover, in tumor cells, aberrant 
activation of ERK1/2 is implicated in inhibition of differentiation and apoptosis.35  Activation 
of ERK1/2 in infected DC by L. amazonensis amastigotes may provide two critical 
mechanisms to ensure parasite success within the mammalian host. First, by targeting 
specific genes for regulation, namely CD40 and IL-12p40, L. amazonensis could interfere 
with proper DC maturation thereby preventing immune detection and induction of a proper 
adaptive immune response. Second, increased activation of host ERK1/2 would promote 
survival of the host cell therefore maintaining a viable host cell for an extended period of 
time.   
ERK1/2 activation as an immunomodulatory mechanism for leishmaniasis has been 
previously described in other cells systems. Leishmania phosphoglycan has been shown to 
inhibit IL-12 production by macrophages via ERK1/2 activation.36  Recent work has 
demonstrated that antibody-opsonized L. amazonensis amastigotes induce ERK1/2 
activation in Balb/c macrophages. Our work using a C3HeB/FeJ mouse model complement 
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these findings, providing further support for ERK in the pathogenesis of L. amazonensis 
infection. We demonstrate that L. amazonensis amastigote infection of BMDC promotes 
increased ERK1/2 activation in the absence of additional activating stimuli. In contrast to 
these findings, Xin et al. observed that both L. amazonensis promastigotes and amastigotes 
both reduce ERK1/2 phosphorylation in the presence or absence of activating stimuli.15 
These differences could be explained by the time points chosen for analysis. Based on our 
data, the 6.5 hour time point occur after the observed peak in ERK1/2 phosphorylation by 
both L. amazonensis amastigotes (7 minutes) and promastigotes (4.5 hours).  
We report here that inhibition of ERK phosphorylation with the ERK inhibitor 
PD98059 prior to BMDC infection with L. amazonensis amastigotes leads to an enhanced 
CD40 surface expression and IL-12p40 production (Fig. 4A and B). In vivo, treatment of 
mice with the orally available ERK inhibitor CI-1040 enhanced CD40 surface expression of 
CD11c+ DC (Fig. 4C and D), but did not result in an increased number of IL-12p40-
producing cells collected from the DLN of L. amazonensis-infected mice (Fig. 4F). We 
hypothesize that the observed decrease in the number of IL-12p40-producing cells from L. 
amazonensis-infected mice, in the presence of ERK inhibition, may be a result of the lower 
number of CD11c+ cells found in the draining lymph node (CD11c+ events with no treatment, 
2818 vs. CD11+ events with CI-1040, 1225).  CI-1040-treatment of Raf-transformed 
hematopoietic cells leads to increased sensitivity to apoptosis.37 We suggest that systemic 
ERK inhibition via treatment with this inhibitor may adversely affect the survival of 
monocytes migrating into the site of infection and later into the draining lymph node. A 
closer analysis of IL-12p40 production of individual CD11c+ events from the DLN of infected 
mice may be required to determine the effects of ERK inhibition on the production of this 
cytokine.  
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Our observation of a more mature DC phenotype following treatment of L. 
amazonensis-infected C3HeB/FeJ mice with the ERK inhibitor CI-1040 complements work 
from our laboratory showing that ERK inhibition can promote parasite killing in L. 
amazonensis-infected macrophages in vitro.19 The data is also consistent with work 
indicating that inhibition of ERK slows disease progression of L. amazonensis-infected 
Balb/c mice.18  Although we did not observe a restoration in IL-12p40 production during in 
vivo L. amazonensis infection, ERK inhibition did enhance CD40 surface expression. 
Previously, it has been shown that CD40-CD40L interactions are important during L. 
amazonensis infection, as deficiencies in this interaction lead to increased susceptibility to 
infection.10 The work presented here indicates that L. amazonensis specifically targets CD40 
expression in vivo, and that we can restore CD40 surface expression by inhibiting 
phosphorylation of ERK. We suggest that the mature phenotype restored to CD11c+ DC via 
ERK inhibition would promote the development of a productive CD4+ T cell response during 
L. amazonensis infection; however, further studies are necessary. The work presented here 
furthers our understanding of host-parasite amastigote-specific interactions and provides 
evidence for the use of ERK inhibitors as immunomodulators to directly enhance the host 
immune response after Leishmania infection.  
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Figure 1. Decreased CD40 expression and IL-12p40-producing cells from DC subsets 
of total draining lymph node cells from L. amazonensis-infected mice at 7 days post-
infection. Mice were infected with L. amazonensis or L. major promastigotes and sacrificed 
at 2 and 7 days post infection. CD11c+ DC subsets from total draining lymph node cells, 
collected on CD19 and CD3 double negative events (A) were analyzed for CD40 surface 
expression via FACS scan. Bar graphs indicate percent CD40 positive (gray, isotype control; 
black, CD40) and mean fluorescence intensity for CD11c+CD11b+ cells at 2dpi (B and D) 
and 7 dpi (C and E). Shown are number of IL-12-producing cells from DLN of mice infected 
with L. amazonensis or L. major at 2dpi (F) or 7 dpi (G) measured via ELispot.  The data is 
from 3 separate experiments; error bars indicate ± standard error of the mean (S.E.M.); (*) 
denotes significant differences, p≤ 0.05. 
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Figure 2. Robust ERK1/2 phosphorylation in L. amazonensis amastigote-infected 
BMDC and delayed ERK1/2 activation following L. amazonensis promastigote 
infection.  BMDC were infected with L. amazonensis or L. major amastigotes (A) or 
promastigotes (B and C). Whole cell lysates were collected at the indicated time points. 
Samples were analyzed via western blot for phosphorylated ERK1/2 (A-C), p38 (D), JNK (E) 
and total ERK1/2, p38 and JNK. Densitometry values were normalized to t-ERK, t-p38 or t-
JNK and then to non-infected controls. Densitometry analysis for at least 3 different 
experiments and representative blots are shown; error bars denote ± standard deviation 
(S.D.); (*) denotes significant differences, p≤ 0.05.
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Figure 3. L. amazonensis amastigotes predominate within infected cells at 4 hours 
post infection. BMDC were infected with L. amazonensis promastigotes within 24 well 
plates. Cover slips were recovered at the indicated time points, fixed and stained. (A) 
Epifluorescent microscopy analysis of BMDC, (100x, oil). Infected cells were determined by 
propidium iodide (PI) nuclear and kinetoplast staining, and promastigotes were 
characterized via C7AE anti-LPG antibody and a secondary Cy2-conjugated antibody. Data 
representative of n = 2. (B) Cover slips were analyzed via light microscopy, (100x, oil). 
Parasite stage was identified by presence or absence of flagellum and by size. Graphs 
indicate the percentage of promastigote-infected cells from total infection rate. Data from at 
least 3 separate experiments; error bars denote ± S.E.M; (*) denotes significant difference, 
p≤ 0.05.  
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Figure 4. ERK inhibition enhances DC maturation phenotype following L. 
amazonensis infection  (A-B) BMDC were pretreated with the ERK inhibitor PD98059 
(20mM) for 30 minutes and then infected with L. amazonensis amastigotes, and activated 
with LPS and IFN-γ. 24 hours-post infection cells were harvested and processed for (A) 
surface CD40 expression and analyzed via FACS scan and (B) supernatants were collected 
to determine IL-12p40 production via ELISA. (C-H) Mice were infected with L. amazonensis 
or L. major promastigotes and then treated with 100mg/kg of CI-1040 via oral gavage 
started on day 0 post infection and for the next seven days, twice daily. On day 7 mice were 
sacrificed; draining lymph nodes were harvested to assess CD40 surface expression on DC 
populations. (C) Representative histograms based on CD11c+CD11b+ population, (gray line, 
isotype control; black CD40). Mean fluorescence intensity of CD40 surface expression on 
CD11c+ cells in L. amazonensis- (D) or L. major-infected mice (E) treated with CI-1040 or 
DMSO-mock control. Number of IL-12p40-producing cells (F and G) as determined by 
Elispot analysis of total draining lymph node cells. Western blot of splenic lysates probed 
with anti-phosphorylated ERK1/2 and anti-total ERK1/2. Data from at least 3 different 
experiments; error bars denote ± S.E.M.; (*) denotes significant differences, p≤ 0.05. 
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Abstract  
Leishmania amazonensis infection of dendritic cells (DC) activates the extracellular 
signal-regulated kinase (ERK)1/2, a member of the mitogen-activated protein kinase 
(MAPK) family. This activation has been shown to lead to an altered DC maturation 
phenotype, which may contribute to non-healing cutaneous leishmaniasis. ERK1/2 
activation following L. amazonensis promastigote infection peaks 4 hours post-infection in 
vitro, when parasites are primarily present within intracellular phagolysosome-based 
parasitophorous vacuoles.  Studies using non-pathogen-based means of ERK1/2 activation 
in cell lines have shown that robust intracellular activation of ERK1/2 from phagolysosomes 
requires the recruitment and association of ERK1/2-specific scaffolding proteins, including 
p14/MP1 and MORG1, on the surface of this intracellular compartment.  Here we identify 
scaffolding module co-localization, specifically the endosomal ERK-related proteins MP1 
and MORG1 with L. amazonensis-containing, LAMP2 positive-phagolysosomes in DC.  This 
is the first time pathogen ERK1/2 activation is correlated to intracellular-induced ERK 
activation and identifies novel signaling cascade components which interact with the L. 
amazonensis parasitophorous vacuole.  
 
 
Introduction  
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 Leishmania parasites have a dimorphic life cycle alternating between the vector and 
the and mammalian host. Once inoculated into the mammalian host, promastigotes are 
internalized by phagocytic cells of the immune system including macrophages and dendritic 
cells (DC). After phagocytosis, promastigotes are found within membrane-bound organelles 
(i.e. phagosomes) of the endocytic pathway. These parasite-containing organelles, also 
referred to as parasitophorous vacuoles (PV), progressively acquire characteristics of late 
endosomal/lysosomal compartments. During this time promastigotes begin the 
differentiation process into amastigotes, the parasite form that persists in the infected 
mammalian host. As intracellular parasites residing in phagocytic cells of the immune 
system, amastigotes must continue to subvert the host cell immune response in order to 
survive. 
Leishmania parasites have been shown to alter host cell processes including host 
cell signaling to promote their survival (reviewed in (17)). Most studies aimed at 
understanding the alteration of host signaling pathways triggered by Leishmania parasites 
have focused on the initial events of host-parasite interactions occurring on the host cell 
plasma membrane. However, Leishmania parasites reside intracellularly within mammalian 
host cells, and it is from these intracellular compartments that they continue to engage host 
cell signaling pathways and interfere with host cell function (12). The molecular mechanisms 
by which Leishmania parasites continue to target host cell processes from within the PV 
remain poorly understood.  
PV are highly dynamic structures, which contain components of host plasma 
membrane, endosomal organelles, and parasite-derived molecules (10). These organelles 
are characterized by an acidified environment and are enriched in late endosomal/lysosomal 
proteins including the lysosomal associated protein 2 (LAMP-2) (2). Classically, late 
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endosomes/lysosomes are the endpoint step in the endocytic pathway and serve as sites for 
degradation of pathogens and other materials (16). Because PV share characteristics of late 
endosomes/lysosomes, newly internalized material and recycled cytoplasmic molecules can 
be delivered to the PV for degradation (6). This provides Leishmania parasites with a 
constant supply of host-derived molecules, including signaling components (receptors, 
kinases, adaptor proteins) and maintains the PV in continuous communication with the 
endocytic pathway of the host cell.  
The concept of the endocytic pathway serving as sites for signal transduction has 
gained increased interest as endocytosis and signal transduction appear to be bidirectionally 
regulated (24). Endocytic internalization of receptors upon ligand binding serves as a 
common regulatory mechanism for receptor desensitization for a variety of receptors, 
including receptor tyrosine kinases (RTK) and G-protein coupled receptors (GPCR) (25). 
Although this process was initially thought to solely serve for signal attenuation, the 
presence of activated epidermal growth factor receptors (EGFR) and its downstream 
effectors on endosome membranes, suggested that signaling may also be initiated from the 
endocytic pathway (9). Endosomes serving as signaling platforms for a variety of receptors 
has been proven by the myriad of signaling proteins found to be associated with endosomal 
compartments and signal attenuation secondary to inhibition of endocytosis or subcellular 
mis-localization of endosomes (reviewed in (7, 25), 26, 28). Critical in mediating activation of 
signal transduction pathways from endocytic compartments are site-specific scaffold 
proteins. Scaffold proteins not only provide targeted location sites for the formation of 
signaling complexes but can also enhance signal transduction (13, 23). 
We have previously demonstrated that Leishmania amazonensis infection of DC 
promotes increased phosphorylation of the extracellular-regulated kinase (ERK) 1/2, which 
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results in an impaired DC maturation phenotype (2). Infection with L. amazonensis 
promastigotes results in ERK1/2 activation at around 3-4 hours post-infection, when 
parasites are predominately found intracellulary within infected cells. This delay in ERK1/2 
activation suggests L. amazonensis is triggering ERK1/2 phosphorylation from within the 
host cell PV. Activation of the ERK pathway from subcellular locations, including endosomal 
organelles, has been previously described (reviewed in (8)). Mediating this process are two 
scaffolding proteins, MEK partner (MP) 1 and MAPK organizer (MORG) 1 (21, 22). We 
sought to determine the mechanism by which L. amazonensis could trigger ERK1/2 
phosphorylation from within the host cell. We tested the hypothesis that MP1 and MORG1 
scaffolding molecules were involved in L. amazonensis-mediated ERK1/2 phosphorylation 
from an intracellular host cell compartment. We find that L. amazonensis-dependent ERK1/2 
enhanced phosphorylation is mediated by live parasites, which are able to undergo stage 
transformation, as heat-killed promastigotes are unable to mediate ERK1/2 activation. We 
find that L. amazonensis parasites are found within late endosomal compartments, 
characterized by association with LAMP-2, and that at time points during peak ERK1/2 
activation, amastigotes predominate within infected cells. We demonstrate intracellular 
phosphorylated ERK1/2, and the ERK1/2-specific scaffold proteins MP1 and MORG1 co-
localizing with parasite-containing organelles. Altogether, our data describes a novel 
Leishmania-dependent mechanism of host cell signaling modulation from subcellular 
compartments, mediated through host cell MAP kinase ERK1/2 scaffolding proteins.  
 
Materials and Methods 
Bone marrow-derived dendritic cells (BMDC) 
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BMDC were cultured in vitro in the presence of 10 ng/ml of murine granulocyte-
macrophage colony-stimulating factor (PeproTech Inc., Rocky Hill, NJ) according to the 
method of Lutz et al. (5, 15). At day 10 of culture BMDC were harvested for use and 
approximately 90% of the cells were  CD11c+ as analyzed via flow cytometry. Where 
indicated, BMDC were treated with Pertusis toxin (100ng/ml) (Calbiochem, San Diego, CA).  
 
Parasite culture and infection  
 Culture of L. amazonensis (MHOM/BR/00/LTB0016) parasites was performed as 
previously described.(11) For in vitro promastigote experiments, stationary phase L. 
amazonensis promastigotes were used. Where indicated, parasites were labeled with 
CellTracker Orange (Invitrogen,Carlsbad, CA). Parasites in PBS were incubated with 0.1uM 
solution of CellTracker dye for 15 minutes at room temperature, washed, and resuspended 
in PBS.  For heat-killed experiments, L. amazonensis promastigotes were diluted to the 
desired concentration and then incubated at 65ºC for 1 hour and placed on ice for at least 
20 minutes prior to use. For in vitro studies, 10-day-old BMDC were incubated at 34°C, 5% 
CO2 with L. amazonensis promastigotes at a cell to parasite ratio of 1:3. 
 
Electrophoresis and immunoblotting 
To make whole cell lysates, 3 x 106 BMDC were resuspended in 400 μl of 1x cell 
lysis buffer (Cell Signaling Technologies, Beverly, MA), supplemented with 1mM 
phenylmethylsulphonyl fluoride (PMSF) and a protease inhibitor cocktail (Roche, 
Indianapolis, IN) immediately prior to use. Samples were incubated on ice for 15 min and 
then centrifuged at 16,000 x g for 10 min at 4ºC. Supernatants were collected as whole cell 
lysates and stored at -80ºC.  
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Immunoblot analysis 
Protein content of all cell extracts was determined via BCA protein assay (Pierce, 
Rockford, IL) according to manufacturer’s recommendations, and all samples were 
normalized to 1mg/ml using distilled water. Samples (20-30 μg of protein) were heated for 4 
min at 95°C in 1x loading buffer and electrophoresis was performed on a 12% sodium 
dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) gel. Gels were 
electroblotted onto polyvinylidene fluoride membranes (PVDF), blocked with 5% bovine 
serum albumin, and probed with antibodies specific for phospho-ERK, total-ERK1/2 (1:1000) 
(Cell Signaling, Beverly, MA) and β-actin (1:5,000) (Sigma, St. Louis, MO). Signals were 
detected with horseradish-peroxidase (HRP)-conjugated goat anti rabbit antibodies 
(1:20,000) (Jackson ImmunoResearch, West Grove, PA) using the SuperSignal West 
chemiluminescent substrate (Pierce, Rockford, IL) and expressed to autoradiography film 
(Midsci, St. Louis, MO). 
 
Intracellular immunofluorescence staining and microscopy analysis 
 1x106 BMDC were plated onto 24-well plates containing tissue cover slips. BMDC 
were infected with CellTracker Orange-labeled L. amazonensis promastigotes at an MOI of 
3:1 and incubated at 34ºC with 5% CO2. Cover slips were harvested and fixed with 4% 
paraformaldehyde in phosphate buffered saline (PBS) for 20 minutes at room temperature 
and washed three times with PBS. BMDC were permeabilized with 0.1% saponin in PBS for 
20 minutes at room temperature. Cells were incubated for 1 hour at room temperature with 
rabbit anti-MP1 (Santa Cruz Biotechnology, Santa Cruz, CA), MORG1 (Abcam, Cambridge, 
MA), pERK1/2 (Cell Signaling, Beverly, MA), and LAMP-2 (eBiosciences) at a 1:100 dilution 
in 0.1% saponin. After incubation, cover slips were washed three times with PBS and 
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incubated for 1 hour at room temperature with rabbit anti-mouse Cy2-conjugated antibody 
(Jackson ImmunoResearch Laboratories, West Grove, PA) at a 1:200 dilution in 0.1% 
saponin. BMDC were counter-stained with DAPI according to manufacturer’s instructions 
(Molecular Probes, Eugene, OR). Cover slips were mounted onto slides using MOWIOL 
(Calbiochem, La Jolla, CA) and viewed using an Olympus IX71 inverted epifluorescence 
scope (Olympus America Inc., Center Valley, PA). Co-localization analyses were carried out 
using NIH Image software (1) and confirmed by sequential scanning confocal microscopy 
using an Olymphus IX81 inverted scope (Olympus America Inc., Center Valley, PA). 
 
Statistical analysis  
 Statistical significances were analyzed using Prism4 (Graphpad Software Inc., La 
Jolla, CA). Differences between groups were determined using Student’s t-tests and two-
way ANOVA. P-values below 0.05 were considered statistically significant.  
 
Results 
Live L. amazonensis promastigotes are required to trigger ERK phosphorylation 
 To demonstrate that the ERK1/2 phosphorylation observed after L. amazonensis 
infection requires live parasites and was not a time-dependent response to parasite 
internalization, we treated bone marrow-derived dendritic cells (BMDC) with either live or 
heat-killed L. amazonensis promastigotes and collected whole cell lysates at the indicated 
time points. Using western blot analysis we measured ERK1/2 phosphorylation induced by 
these two treatments. As previously demonstrated (5), infection of BMDC with live L. 
amazonensis promastigotes induced significantly increased ERK1/2 phosphorylation as 
compared to BMDC treated with heat-killed parasites (Figure 1). This indicates that L. 
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amazonensis-mediated activation of ERK1/2 is dependent on cellular interaction with live 
parasites. 
 
L. amazonensis promastigotes reside in late endosomal compartments and undergo 
expected developmental progression into amastigotes 
 Upon phagocytosis, Leishmania promastigotes are contained within a double 
membrane-bound compartment, referred to as a parasitophorous vacuole (PV). During the 
process of phagosome maturation, promastigotes undergo developmental and 
morphological changes becoming amastigotes. It has been previously shown that newly 
formed phagosomes following Leishmania internalization in DC rapidly acquire late 
endosomal markers including LAMP-1 and -2 (14). We wanted to further characterize the 
phagosomal compartment and developmental stage of the parasite during the time of 
observed ERK1/2 phosphorylation. Using L. amazonensis promastigotes stained with a 
fluorescent dye, CellTracker orange, we infected BMDC and harvested cells at 2, 3 and 4 
hours post-infection and characterized the phagosomal compartment via immuno-
fluorescence analysis and epifluorescent microscopy. Green, punctuate cytosolic staining 
indicated presence of LAMP-2 (Figure 2A, second panel). At the time points analyzed, L. 
amazonensis parasites were found within membrane-bound compartments that tightly 
delineated the shape of the parasite (Figure 2A, third panel). LAMP-2 was also observed to 
closely follow parasite outline at all time points analyzed, suggesting association with the 
organelles containing L. amazonensis (Figure 2A, second and fourth panels, white arrows). 
These data support previous findings indicating that PV maturation occurs within 1 hour 
after infection (14). In addition, the data indicates that at the time of ERK1/2 
phosphorylation, L. amazonensis is located within late endosomal/lysosomal compartments.  
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To further characterize parasite development within infected BMDC, we sought to 
determine the percentages of promastigotes versus amastigotes just before (2hr post-
infection) and during ERK1/2 activation (4hr post-infection). BMDC cultured on coverslips 
were infected with L. amazonensis promastigotes and then harvested at 2 and 4 hours post 
infection and analyzed via light microscopy. Promastigotes and amastigotes were 
differentiated based on morphology, presence or absence of a flagellum, and size 
(amastigotes, <5μm). As expected, while promastigotes predominated within infected cells 
at 2 hours post-infection, there was a significant increase in the number of intracellular 
amastigotes at 4 hours post-infection (Figure 2B). Altogether these data suggest that BMDC 
ERK1/2 phosphorylation occurs when L. amazonensis parasites are found within late 
endosomal/lysosomal compartments and differentiating into amastigotes.  
 
Intracellularly-phosphorylated ERK co-localizes with L. amazonensis  
We have previously shown that when BMDC are infected with L. amazonensis 
promastigotes there is significant and robust ERK1/2 phosphorylation observed 3-4hours 
post-infection (5). As shown in Figure 2A, at this point, parasites are intracellular, within late 
endosomal compartments. We hypothesized that L. amazonensis-mediated ERK1/2 
activation is initiated from this intracellular compartment. To test this hypothesis we infected 
BMDC with L. amazonensis promastigotes stained with a fluorescent dye and detected the 
location of phosphorylated ERK1/2 using intracellular immuno-fluorescent analysis and 
epifluorescence microscopy. Green cytosolic staining indicated the presence of phospho-
ERK1/2 in BMDC (Figure 3A, second panel). Immunofluorescence, particle co-localization 
analysis showed that phopho-ERK1/2 co-localized with L. amazonensis promastigotes (red) 
at all time points analyzed, 2-4 hrs (Figure 3A, fourth panel, 3B). We confirmed these 
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findings via sequential scanning confocal microscopy. This data suggests that ERK1/2 
phosphorylation is occurring from intracellular, parasite-containing, organelles.  
 
Scaffold proteins MP1 and MORG1 associate with L. amazonensis-containing organelles 
 MP1 and MORG1 have been recently characterized as scaffold proteins for late 
endosomal-mediated ERK1/2 phosphorylation (21, 29). Moreover, while MP1 directly 
localizes with late endosomes via it interaction with p14,  MORG1 can only form a complex 
on late endosomes in the presence of MP1, as the two scaffold proteins directly interact (27, 
29). Given that L. amazonensis parasites are found within late endosomal compartments, 
and that phopho-ERK1/2 co-localizes with intracellular parasites, we hypothesized that 
scaffold protein(s) may function to mediate activation of ERK1/2 from intracellular parasite-
containing organelles.  
To analyze the role of MORG1 in our system, we utilized intracellular immuno-
fluorescence analysis and epifluorescence microscopy to determine any potential 
association between MORG1 and parasite-containing organelles following infection. 
Immunofluorescence analysis indicated green cytosolic distribution for MORG1, along with 
co-localization of this scaffold protein with intracellular parasites (Figure 4A). Particle co-
localization quantitative analysis shows co-localization between MORG1 and L. 
amazonensis during all time points studied (Figure 4B). Our findings were confirmed by 
sequential scanning confocal microscopy.  
Since MORG1 requires MP1 to form a scaffolding complex on late endosomes, we 
hypothesized that MP1 must also be recruited to parasite-containing organelles. Again using 
immunofluorescence, and particle co-localization analysis, we show that MP1 co-localizes 
with L. amazonensis in infected cells (Figure 4C and D). Altogether these data suggest that 
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MORG1 and MP1 are recruited to parasite-containing organelles and are likely to mediate 
intracellular L. amazonensis-dependent activation of ERK1/2 within infected cells.   
 
Pertussis toxin treatment reduces L. amazonensis-dependent ERK1/2 phosphorylation 
Little is known regarding the regulation and recruitment of MP1 or MORG1 to late 
endosomal compartments. However, of the two, MORG1 appears to show more selectivity 
as it is only recruited after triggering of G protein-coupled receptor (GPCR) signaling (24).  In 
order to further test the role of MORG1 in our system, we pre-treated BMDC with Pertussis 
toxin (PTX), which binds to the Gα (G-i/o subfamily) subunit of G proteins and prevents their 
activation. When BMDC were pre-treated with PTX and then infected with L. amazonensis 
promastigotes, we observed a significant decrease in ERK1/2 phosphorylation as compared 
to untreated, infected cells (Figure 5A). In addition, confocal microscopy analysis of the 
location of MORG1 in BMDC infected with L. amazonensis following PTX treatment shows 
no co-localization of this scaffold protein and the parasite (Figure 5B). Similar to the effect 
on MORG1 recruitment, no co-localization of MP1 and L. amazonensis-containing 
organelles was observed (Figure 5C). In addition, PTX treatment altered the cytosolic 
distribution of MP1 (Figure 5C) as compared to non-treated cells (Figure 4C). These data 
suggest that activation of the Gα-i/o subfamily of GPCR may be involved in mediating 
enhanced L. amazonensis-dependent ERK1/2 activation, possibly through recruitment of 
MORG1 to late endosomal compartments.  
 
Discussion 
 Our understanding of the mechanisms employed by Leishmania parasite to modulate 
host cell signaling is limited (17). Previous works assessing the host cell response to 
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Leishmania infection have focused on the events taking place during initial host-pathogen 
interactions at the host’s plasma membrane. However, in the mammalian host, Leishmania 
parasites reside intracellularly within parasitophorous vacuoles (PVs), and it is from within 
these membrane-bound compartments that they continue to modulate the host cell 
response (12).  Understanding how Leishmania harness the host cell immune response may 
provide insight into therapeutic approaches to combat infection.  
As potent antigen presenting cells, dendritic cells (DC) play a critical role in the 
initiation of adaptive immune responses (4). Interfering with proper DC maturation and 
function can be detrimental to the ensuing immune response. The balance of particular 
molecular signaling cascades has been shown to affect the maturation process of DC (3, 18, 
19). Pathogen-mediated modulation of these signaling pathways could lead to improperly 
activated DC that subsequently promote a non-polarized adaptive immune response.   We 
have previously shown that L. amazonensis infection can impair proper DC maturation via 
activation of ERK1/2 (5). Our data indicated that following infection with L. amazonensis 
promastigotes, robust ERK1/2 activation was not observed until hours post infection, when 
parasites were predominantly found intracellulary. This suggested that L. amazonensis 
could be mediating activation of ERK1/2 from within the PV. Recent work has shown that 
infection with L. amazonensis promastigotes leads to activation of the phosphoinositide 3-
kinase (PI3K) pathway (20). Interestingly, PVs were observed to contain lipid products of the 
PI3K pathway for at least 12 hours post infection, suggesting that these endosomal 
organelles could serve as activation sites for downstream kinases of this pathway, such as 
protein kinase (PK)B/Akt (12). These data support the possibility of other pathways being 
activated from PVs during Leishmania infection. In this paper, we sought to characterize a 
mechanism by which L. amazonensis parasite could trigger ERK1/2 activation from within 
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PVs. The data presented here point to a potential molecular mechanism of L. amazonensis-
dependent ERK1/2 signaling via recruitment of host scaffold proteins, MP1 and MORG1. 
While L. amazonensis amastigote infection triggers ERK1/2 phosphorylation within 
minutes of parasite exposure, L. amazonensis promastigote infection of bone marrow-
derived dendritic cells (BMDC) results in delayed ERK1/2 phosphorylation, not observed 
until hours post-infection (5). Treatment of BMDC with heat-killed L. amazonensis 
promastigotes resulted in a significant decrease in ERK1/2 phosphorylation as compared to 
BMDC treated with live parasites (Figure 1). This data indicated that ERK1/2 
phosphorylation is dependent on the presence of viable parasites, which can undergo stage 
transformation, and is not a time-based response of promastigote phagocytosis. Moreover, 
the data suggests that ERK1/2 signaling is actively modulated by intracellular L. 
amazonensis parasites. While both promastigotes and amastigotes can initiate infection, the 
amastigote form of the parasite predominates and persists within host cells, and must 
subvert the host immune response from within an intracellular compartment. Amastigotes 
are capable of altering multiple host cell processes, including host cell signaling, to establish 
infection and persist within phagocytic cells of the immune system (reviewed in (12)). It 
could be suggested that the delay in ERK1/2 phosphorylation following promastigote 
infection is due to a requirement for a specific amastigote-derived ligand and/or specific time 
or dose-dependent conditions within the PV that promote signaling through this MAP kinase 
pathway.   
In order to assess parasite localization within BMDC, we characterized parasite-
containing organelles via immunofluorescence using the lysosomal-associated membrane 
protein 2 (LAMP-2) (Figure 2A). LAMP-2-positive organelles are characterized as late 
endosomal/lysosomal compartments, which is where Leishmania parasites have been 
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previously shown to reside (reviewed in (6)). Lysosomal compartments contain a highly 
hydrolytic, highly acidic environment, specialized in the degradation of material within 
membrane-trafficking pathways, including pathogens (16). While promastigotes are not well 
adapted to survive within lysosomes, amastigotes can survive and multiply under these 
harsh conditions. Increased temperature and reduced pH are important triggers for 
amastigote differentiation (31). The presence of L. amazonensis within LAMP-2-positive 
compartments would suggest a stage of infection when promastigotes are undergoing the 
differentiation process into amastigotes.  
Using light microscopy we assessed amastigote differentiation within infected cells. 
Promastigotes predominated within infected cells at 2 hours post-infection, while by 4 hours 
post-infection, the amastigote form predominated within infected BMDC (Figure 2B). This 
switch from promastigotes to amastigotes correlates with the onset of ERK1/2 activation 
observed following L. amazonensis promastigote infection. Taken together, these data 
suggest that an amastigote-derived ligand may be required to trigger the ERK1/2 pathway. 
This is further supported by previous findings of our laboratory showing the almost 
immediate ERK1/2 phosphorylation following L. amazonensis amastigote infection.  
We and others have previously reported activation of the MAP kinase ERK pathway 
during L. amazonensis infection (5, 30). Here we demonstrate for the first time that 
phosphorylated ERK1/2 is found to co-localize with intracellular parasites (Figure 3A and B), 
suggesting activation of this kinase from an intracellular compartment. While the plasma 
membrane is the canonical site for initiation of signal transduction, MAP kinase signaling 
from intracellular organelles has been previously described (reviewed in (8)). Scaffold 
proteins have emerged as critical mediators in regulation of ERK1/2 signaling from 
subcellular compartments. These molecules act by binding one or more signaling 
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components (kinases) to regulate their association with other kinases or substrates, 
enhance their activity, and determine specific subcellular localization of the signaling 
complex (13, 23).  
MP1 and MORG1 are two such scaffold proteins shown to mediate ERK1/2 
activation from late endosomal compartments. We hypothesized that either MP1, MORG1 or 
both, could be recruited to parasite-containing organelles and mediate activation of the 
ERK1/2 pathway. Here we show that both MP1 and MORG1 co-localize with L. 
amazonensis within infected BMDC from 2-4 hours post-infection (Figure 4A and B), when 
robust ERK1/2 phosphorylation was previously demonstrated (5). Previous studies 
demonstrated that MORG1 is recruited under specific signaling conditions, specifically, 
when G-protein coupled receptors (GPCR) are stimulated (29). Treatment of L. 
amazonensis-infected BMDC with Pertussis toxin (PTX), a known Gαi/o subunit inhibitor, led 
to a decrease in ERK1/2 phosphorylation as compared to non-treated cells (Figure 5A). This 
observation suggested a potential role for Gαi/o signaling during L. amazonensis-dependent 
ERK1/2 activation. Our data would suggest that stimulation of Gαi/o during internalization of 
L. amazonensis may promote MORG1 recruitment to late endosomal compartments and 
subsequent enhanced ERK1/2 phosphorylation. This is supported by the finding that during 
PTX treatment we observe a lack of MORG1-L. amazonensis co-localization via confocal 
microscopy (Figure 5B, top panel). 
Altogether, our data describes a novel L. amazonensis-mediated mechanism of 
ERK1/2 activation from an intracellular compartment. Intracellular L. amazonensis parasites 
actively utilize host scaffold proteins to trigger activation of the MAP kinase ERK1/2 
pathway.  We have previously shown that activation of this pathway following L. 
amazonensis infection leads to impaired DC maturation and that inhibiting ERK1/2 activation 
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leads to restoration of the DC maturation phenotype in vitro and partial recovery in vivo (5). 
Given the ubiquitous nature of ERK1/2 signaling and the myriad cellular processes in which 
it is involved, systemic inhibition of ERK could lead to non-desirable host side effects. 
Through characterization of a specific, scaffold-mediated mechanism of ERK1/2 activation, it 
is feasible to envision the development of treatment options to specifically modulate 
pathogenic ERK1/2 phosphorylation, sparing more universal functions. These therapeutic 
treatments could serve to treat not only L. amazonensis infection, but other diseases where 
aberrant activation of ERK1/2 leads to disease.  
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Figure 1 Live L. amazonensis promastigotes are required to promote phosphorylation 
of the MAP kinase ERK1/2. BMDC were treated with live or heat-killed L. amazonensis 
promastigotes and incubated at 34ºC with 5% CO2. BMDC were harvested at the indicted 
time points and total cell lysates were made. Samples were analyzed via western blot for 
phosphorylated and total ERK1/2. Densitometry values were normalized to total ERK and 
then to non-infected controls. Densitometry analysis of at least three different experiments 
and representative blot are shown; error bars denote ±SEM, (*) denotes statistically 
significant differences, p<0.05. 
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Figure 2 L. amazonensis parasites are found within LAMP-2-positive compartments 
and amastigotes predominate within infected cells at four hours post-infection.  
BMDC in 24 well plates containing glass coverslips were infected with CellTracker orange-
labeled or unlabeled L. amazonensis promastigotes. Coverslips were recovered at the 
indicated time points, fixed and stained. (A) Sequential scanning confocal microscopy (x60, 
oil) analysis of BMDC infected with L. amazonensis (red) and intracellular LAMP-2 (green) 
(upper panel) at 3 hours post infection. LAMP-2 can be observed delineating the outline of 
L. amazonensis (top panel, second column, white arrows) and co-localizing with the parasite 
(top panel, fourth column, areas of yellow). Bottom panel shows control staining for LAMP-2 
with secondary antibody only. Data representative of at least three different experiments. (B) 
Coverslips were analyzed via light microscopy (x100, oil). Parasite stage was determined by 
presence of absence of flagellum and by size. Graph indicates the percentage of cells 
infected by either or both forms. Representative images for both time points are shown. 
Data from at least three different experiments; error bars denote ±SEM; (*) denotes 
statistically significant differences, p<0.05. 
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Figure 3 Co-localization of L. amazonensis and intracellular phosphorylated-ERK1/2. 
BMDC in 24 well plates containing glass coverslips were infected with CellTracker orange-
labeled L. amazonensis promastigotes. Coverslips were recovered at the indicated time 
points, fixed and stained. (A) Sequential scanning confocal microscopy (x60, oil) analysis of 
L. amazonensis (red) and intracellular phospho-ERK1/2 (green) at 3 hours post-infection. 
Co-localization of L. amazonensis and phospho-ERK1/2 is observed (top panel, fourth 
column, areas of yellow). Secondary only control for phosphor-ERK1/2 staining (bottom 
panel, second column). (B) Immunofluorescence, particle co-localization analysis of L. 
amazonensis and phospho-ERK1/2 during time course of infection. Graph indicates mean 
gray value (sum of the gray values of all the pixels in a selected area divided by the number 
of pixels in that area) of phospho-ERK1/2 signal where parasites were localized. Values 
were normalized to secondary antibody only control. Data from at least three separate 
experiments; error bars denote ±SEM.  
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Figure 4 Co-localization of the scaffold proteins MORG1 and MP1 with L. 
amazonensis within infected BMDC. BMDC in 24 well plates containing glass coverslips 
were infected with CellTracker orange-labeled L. amazonensis promastigotes. Coverslips 
were recovered at the indicated time points, fixed and stained. Sequential scanning confocal 
microscopy (x60, oil) analysis of L. amazonensis (red) and intracellular (A) MORG1 or (C) 
MP1 (green) at 3 hours post-infection. Images indicate areas of co-localization between 
parasite and MORG1 and MP1, as indicated by areas of yellow (top panels, fourth column, 
white arrows). Immunofluorescence, particle co-localization analysis of L. amazonensis and 
(B) MORG1 or (D) MP1. Graphs indicate mean gray value of MORG1 or MP1, signal in 
areas where parasites were localized, as described in Figure 3. Values were normalized to 
secondary antibody only control. Data from at least three separate experiments; error bars 
denote ±SEM.  
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Figure 5 Pertussis toxin treatment reduces L. amazonensis-dependent ERK1/2 
phosphorylation and MORG1 co-localization. (A) BMDC were infected with L. 
amazonensis promastigotes and left untreated or treated with Pertussis toxin (100ng/ml) 
and incubated at 34ºC with 5% CO2. BMDC were harvested at the indicted time points and 
total cell lysates were made. Samples were analyzed via western blot for phosphorylated 
and total ERK1/2. Densitometry values were normalized to total ERK and then to non-
infected controls. Densitometry analysis of at least three different experiments and 
representative blot are shown; error bars denote ±SD. (B) BMDC in 24 well plates 
containing glass coverslips were infected with CellTracker orange-labeled L. amazonensis 
promastigotes and left untreated or treated with Pertussis toxin (100ng/ml) . Coverslips were 
recovered at the indicated time points, fixed and stained. Images of confocal microscopy 
(x60, oil) analysis of L. amazonensis (red) and intracellular MORG1 (top panel) or MP1 
(second panel) (green), at 3 hours post-infection. PTX treatment inhibits MORG1 co-
localization with L. amazonensis; no areas of yellow are present (top panel, fourth column). 
Secondary only antibody control for MORG1 (bottom panel).  
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CHAPTER 5: GENERAL CONCLUSIONS 
 
Summary 
 The first part of the work presented in this dissertation describes for the first time the 
temporal immune response to natural autochthonous Leishmania infantum infection in the 
United States. Clinical disease progression within the Foxhound population of the United 
States recapitulates immune dys-regulation described in endemic patients. Our data 
indicates that infected animals may initially develop an antigen-specific, IFN-γ-producing, 
lymphoproliferative CD4+ T cell response, which can control infection. This is supported by 
the low to undetectable levels of blood parasites and the overall subclinical status of these 
animals. In contrast, animals showing signs of disease progression demonstrate a waning 
CD4+ T cell proliferative response, decreased IFN-γ production and a concomitant increase 
of production IL-10 and immunoglobulins. In these animals, there is an increased parasite 
burden detectable in blood, which may be directly correlated to a non-productive immune 
response.  
In endemic regions, dogs are the primary reservoir for L. infantum and are 
considered the most significant risk factor predisposing humans to infection. Early detection 
and treatment of infected dogs are important in limiting potential human transmission. Our 
work indicates that given the temporal variability in the immune response to L. infantum 
infection, a variety of immune parameters (i.e. antigen-specific proliferation, levels of IFN-γ 
and IL-10, antibody production, and parasite burden) should be considered to better 
prognosticate resistance versus susceptibility to infection and clinical disease. Ultimately 
understanding the causal relationship between these parameters may provide insights into 
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the mechanisms leading to disease progression and consequent development of 
immunotherapies. 
 The second part of the work presented in this dissertation utilizes a different model 
of Leishmania infection, murine cutaneous leishmaniasis, to dissect host-parasite 
interactions that lead to disease susceptibility. We demonstrate that infection of dendritic 
cells (DC) with L. amazonensis leads to an impaired maturation phenotype characterized by 
decreased surface expression of CD40 and production of IL-12p40, as compared to L. 
major-infected DC. Moreover, this immature phenotype results specifically from in vitro 
infection with the amastigote form of the parasite. These data are consistent with the 
observed lack of T cell polarization observed following L. amazonensis infection resulting in 
non-healing, chronic disease.  
Initial assessment of DC maturation following L. amazonensis amastigote infection in 
vitro, indicated that CD40 expression and IL-12p40 production were specifically targeted for 
modulation, as other maturation markers, CD80 and CD86, were expressed in comparable 
levels to L. major-infected DC. This impaired maturation phenotype was mediated by the 
amastigote form of the parasite, as promastigote infection did not affect CD40 expression or 
IL-12p40 production. Ex vivo analysis of DC from the draining lymph node of either L. 
amazonensis- or L. major-infected mice supported our in vitro findings. Decreased CD40 
surface expression and IL-12p40 production from CD11c+ cells from L. amazonensis-
infected mice was observed as early as 7 days post-infection as compared to L. major.  In 
contrast, at 2 days post-infection, no differences were observed between the two infections. 
The temporal difference (2 days vs. 7 days) observed in vivo were taken to emphasize times 
when promastigote versus amastigote infection is likely to predominate. This data supports 
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our in vitro findings suggesting that the amastigote form of the parasite is responsible for 
modulation of CD40 expression and IL-12p40 production.  
Characterization of the molecular mechanisms leading to impaired DC maturation 
indicated that L. amazonensis amastigotes induced rapid and significant phosphorylation of 
the MAP kinase ERK1/2, observed within minutes of exposure of DC in vitro to the parasite. 
Infection with L. amazonensis promastigotes also led to increased ERK1/2 phosphorylation 
as compared to L. major infection; however, this phosphorylation was delayed several 
hours, between 3-4.5 hours post-infection. 
In vitro inhibition studies determined that treatment of DC with a MEK—upstream 
kinase of ERK inhibitor—PD98059, led to enhanced surface CD40 expression and IL-12p40 
production following L. amazonensis-amastigote infection as compared to non-treated cells. 
Treatment of L. amazonensis-infected mice with the highly-specific MEK inhibitor, CI-1040, 
enhanced surface CD40 expression. Together, this data indicates that L. amazonensis 
amastigotes, through activation of the MAP kinase ERK1/2, inhibit the ability of DC to 
undergo proper maturation in vivo.  
The delay in ERK1/2 phosphorylation following L. amazonensis promastigote 
infection indicated that the parasite-mediated signaling was being triggered from an 
intracellular compartment within the infected host. Exposure of DC to heat-killed 
promastigote parasites did not result in ERK1/2 phosphorylation as compared to live L. 
amazonensis promastigote infection. This data suggested that the delayed ERK1/2 
phosphorylation was not a pre-determined effect of parasite internalization. Moreover, 
immunofluorescence analysis of intracellular staining for phosphorylated-ERK1/2 
demonstrated a co-localization between the parasite and activated ERK1/2, suggesting 
ERK1/2 phosphorylation was occurring around the parasite and not from the plasma 
131 
 
 
 
membrane. ERK1/2 activation from intracellular compartments requires the recruitment of 
scaffold proteins to these specific sites. Immunofluorescence analysis indicates that two 
scaffold proteins specific for late endosomal compartments, MP1 and MORG1, co-localize 
with L. amazonensis-containing organelles.  
Altogether, our data suggest that a possible mechanism of immune evasion by which 
L. amazonensis directly utilizes host-derived signaling components to trigger intracellular 
ERK1/2 activation. Activation of the ERK1/2 pathway negatively affects the maturation 
phenotype of DC, and thus negatively affects the ensuing immune response.  
 
Discussion 
North American canine visceral leishmaniasis 
Although endemic in many parts of the world, canine visceral leishmaniasis (CVL) is 
an emerging disease in the United States Foxhound population. Infection with L. infantum 
does not always equate with clinical disease. When disease progression occurs, clinical 
presentation manifests in a broad spectrum ranging from asymptomatic to disseminated, 
polysymptomatic disease. Moreover, the observed disease progression and the immune 
response of L. infantum-infected Foxhounds are very similar to naturally- and 
experimentally-infected dogs (5, 13), making natural, autochthonous L. infantum infection in 
this country a unique opportunity to study VL.  
Host protection against VL requires a pro-inflammatory, T helper (TH) 1 immune 
response, as characterized by the production of interleukin (IL)-12 by antigen presenting 
cells and IL-2, tumor necrosis factor alpha (TNF-α) and interferon (IFN)-γ by T cells (29, 30). 
Infected macrophages are activated by IFN-γ and TNF-α to kill intracellular amastigotes via 
the L-arginine nitric oxide pathway (26, 28, 41). In contrast, susceptibility to disease is 
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characterized by the appearance of Leishmania-specific lymphoproliferative 
unresponsiveness, decreased production of IFN-γ following Leishmania antigen stimulation, 
and a concomitant immune-suppressive response (12, 36). Susceptibility to L. infantum 
infection is unique in that the susceptible response is often secondary to an established 
productive immune response. The factors that control the balance between susceptible and 
protective immune responses remain poorly understood.  
 In our studies of L. infantum-infected Foxhounds, we were able to characterize the 
temporal immune response to this parasite as described in Figure 1. In our cohort of animals 
we were able to observe three different stages in the immune response to L. infantum as 
infection progressed from asymptomatic to oligosymptomatic and to full clinical VL. Our data 
indicates that infected animals may initially develop a productive, IFN-γ-mediated immune 
response, able to control infection. During this stage, parasite-specific antibodies and blood 
parasites in these animals are low to undetectable. While some infected animals may 
remain asymptomatic for years, showing no signs of disease, other animals begin to show 
signs of disease progression. During this second phase, infected animals have an antigen-
specific proliferative response and IFN-γ production, in addition to increased production of 
IL-10 and antigen-specific antibodies. Blood parasites are also more readily detectable, 
indicating increased levels of circulating parasites. In the third stage of infection, during 
clinical disease, the initial protective, TH1-mediated immune response wanes, while levels of 
IL-10 and antigen-specific antibodies are significantly increased. Loss of the antigen-specific 
CD4+ T cell proliferative response and IFN-γ production have been previously described as 
one hallmark of disease progression (24). In the absence of IFN-γ, macrophages are not 
properly activated to kill intracellular parasites. In addition, increased production IL-10 leads 
to alternately activated macrophages, which are also unable to mediate parasite killing. With 
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decreased parasite clearance, there is an increase in parasite burden in tissues and blood. 
During this non-productive, immune-suppressive response, systemic parasite dissemination 
goes uncontrolled leading to full-blown clinical disease.  
Based on the spectrum of immune responses we observed in the L. infantum-
infected animals studied here, it is clear that no one clinical parameter can be used to 
predict in advance which infected dogs will likely become clinically ill. Our data indicates that 
several key changes in clinical parameters should be considered including a rise in antibody 
production, a decrease in the proliferative and IFN-γ-mediated CD4+ T cell response, a 
progressive increase in IL-10 production, and increased parasite burden. While this 
information is critical during diagnosis and prognostication of disease progression, the 
cause-and-effect relationship between these parameters remains uncharacterized. 
The initial TH1 immune response observed in our cohort of L. infantum-infected dogs 
suggests that these animals are capable of inducing a protective response and controlling 
infection. This has been previously observed both in dogs and humans in previous studies, 
showing that subclinical and cured individuals are capable of mounting antigen-specific IFN-
γ responses following Leishmania stimulation in vitro, are resistant to reinfection and 
become leishmanin skin test positive, suggesting no inherent defect in the antigen-
dependent TH1 immune response (7, 11, 42). The appearance of an immune-suppressive 
response characterized by increased production of IL-10 in serum and lesional tissues has 
been proposed to be responsible for the immunological changes that result in disease 
progression (24). Since animals can remain infected for years, it has been suggested that 
IL-10 production is triggered as a homeostatic response to prevent self-mediated tissue 
damage due to the ongoing inflammatory immune response. IL-10 has pleotropic 
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deactivating effects on the immune response and can be produced by a variety of cell types 
including macrophages, dendritic cells, B cells and T cells.  
To date, the cellular source of IL-10 during canine VL has not been determined. In 
humans, a recent study implicated a population of CD25-Foxp3- T cells in the production of 
IL-10 (23). These T cells arise in the periphery, are antigen driven and produce large 
amounts of IL-10, different from naturally-occurring, CD25+Foxp3+ T regulatory cells. The 
generation of such cells has been previously described in an experimental model involving 
repeated antigenic peptide stimulation (39). It is feasible that IL-10-producing, antigen-
specific T cells are playing a role in our model of canine VL. While we have not tested this 
hypothesis directly, we do observe an antigen-specific IL-10 response from PBMC 
stimulated with L. infantum antigen, and an increase in blood-parasite burden. Higher 
antigenic load would promote continual antigen presentation in the presence of 
inflammation, which may in part lead to the generation of adaptive tolerogenic T cells (2, 15, 
40).  
High levels of antigen have also been associated with the induction of T cell 
exhaustion (4, 21). Exhausted T cells are characterized by decreased antigen-specific 
proliferation and reduced effector function, including cytokine production. Most models of T 
cell exhaustion have focused on CD8+ T cells following viral infection and less is known 
regarding this effect on CD4+ T cells. Recently, using a mouse model of visceral 
leishmaniasis, it was shown that following L. donovani infection; CD8+ T cells became less 
functional, characterized by decreased IFN-γ production, and weak proliferative responses 
(17). Clinical disease in our L. infantum-infected Foxhounds is characterized by a loss in 
CD4+ antigen-specific lymphoproliferation and IFN-γ production, which can be explained in 
part by exhaustion of the T cell compartment.  
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While a loss in the cellular immune response to L. infantum signals disease 
progression, the appearance of a measurable humoral response during visceral 
leishmaniasis is associated with failure to control infection.  There is a strong correlation 
between the levels of immunoglobulins (Ig), clinical status, and parasite burden (33). The 
humoral immune response observed in L. infantum-infected Foxhounds recapitulates these 
findings (5). The marked increased in antigen-specific IgG production in infected animals 
suggests the generation of T cell help associated with antibody production (TH2).  Yet, 
infected animals transitioning into disease progression do not show a clear TH1/TH2 
dichotomy pattern as mixed TH1/TH2 responses have been observed in both subclinical and 
clinical animals, albeit susceptible animals showing slightly higher expression of IL-4 and IL-
10 mRNA (27). To date, production of IL-10 is thought to promote a humoral response by 
enhancing plasma cell survival and subsequent antibody production (24). However, the 
exact mechanism leading to the increased IgG production in infected animals remains 
poorly understood. We would propose that again increased antigen burden could explain the 
observed immune-dysregulation. It has been postulated that the amount and type of antigen 
can regulate the type of immune response (44). During disease progression and 
concomitant higher parasite burden, it is feasible that antigens are more readily presented to 
B cells in secondary lymphoid organs leading to their activation (3).  
We would hypothesize that immune dysregulation observed in L. infantumi-infected 
Foxhounds results from an initial TH1 immune response which is not completely efficient at 
parasite clearance (i.e. no sterile cure). Under these conditions, parasites would slowly 
accumulate in infected tissues even under anti-Leishmania, inflammatory conditions. Over 
time, the immune response, either due to chronic antigen stimulation and/or inflammation-
induced tissue damage, would transition into an alternative immune response. In the case of 
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L. infantum infection, the alternate immune response leads to immune-suppression, which 
leads to further increases parasite burden and promotion of disease progression.  
So far, we have assumed that increased antigen burden and chronic antigen 
exposure may lead to changes in the CD4+ T cell and humoral responses. However, it is 
also feasible that increased antigen burden may be a secondary outcome to an already pre-
disposed condition, where immune-suppression is inherent in the initial response of 
susceptible individuals. While we propose a one-way regulation of antigen and immune dys-
regulation, we cannot discard the possibility of the opposite playing a role, or both acting 
side-by-side. Other factors including genetic predisposition and/or environmental conditions 
may also be responsible for controlling disease outcome. Ultimately, understanding how 
these immunological parameters interact with each other would provide insight into the 
mechanisms leading to disease susceptibility during VL and other similar chronic diseases.  
 
L. amazonensis-mediated modulation of DC signaling pathways and maturation   
Infection of C3HeB/FeJ mice with L. amazonensis leads to chronic, non-healing 
disease, characterized by a non-polarized immune response with low to undetectable levels 
of both IFN-γ and IL-4 (1, 16). Analysis of antigen-responsive CD4+ T cells from C3HeB/FeJ 
mice chronically infected with L. amazonensis, indicate that these cells have an impaired 
ability to transition from a naïve to an effector phenotype (32). Defects in DC maturation 
may, in part, contribute to the non-polarized T cell phenotype observed during L. 
amazonensis infection (32), and lead to a non-healing immune response. 
L. amazonensis infection both in vitro and in vivo results in DC with an impaired 
maturation phenotype characterized by decreased surface expression of CD40 and IL-
12p40 production. CD40 and IL-12 are critical in the induction of TH1 immune responses and 
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defects in both have been shown to lead to disease susceptibility during Leishmania 
infection (8, 19, 20, 37). DC with deficiencies in both CD40 surface expression and IL-12p40 
production may be unable to properly prime CD4+ T cells and promote TH1 polarization. 
Improper or insufficient activation of DC can promote non-polarized, often tolerogenic, 
immune responses like those observed following L. amazonensis infection.  
Both morphological forms of Leishmania parasites, promastigotes and amastigotes, 
are capable of initiating mammalian infection. However, Leishmania amastigotes 
predominate as the life form within the mammalian host and therefore to survive need to 
avoid host detection and elimination. Leishmania amastigotes have been shown to interfere 
with host cell function, including modulation of signaling pathways, suppression of 
antimicrobial and pro-inflammatory mediators, and induction of cytokines that promote 
disease progression (14, 25). In support of these findings, we found L. amazonensis 
amastigotes to be responsible for modulating DC maturation, as promastigote infection did 
not lead to the observed impaired phenotype.  
Consistent with other reports indicating an immunomodulatory role for MAP kinase 
ERK during L. amazonensis infection (10, 43), we found that L. amazonensis amastigote 
infection of DC leads to phosphorylation of ERK1/2. ERK activation has been shown to 
negatively regulate DC maturation, characterized by decreased expression of surface co-
stimulatory molecules and cytokine production (31, 34). Both CD40 and IL-12p40 
expression can be negatively regulated by activation of ERK1/2 (22). When ERK 
phosphorylation was inhibited, DC surface expression of CD40 increased both in vitro and in 
vivo, and production of IL-12p40 was enhanced in vitro. While ERK inhibition in vitro fully 
restored this CD40/IL-12p40 maturation phenotype of infected DC, in vivo inhibition only 
resulted in partial restoration of phenotype. While these findings support the pathogenic role 
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of ERK during L. amazonensis infection, they also suggest that during in vivo infection other 
L. amazonensis-mediated immune regulatory mechanisms may be at work, which are not 
responsive to ERK inhibition. In addition, during our in vivo analysis of mice treated with an 
ERK1/2 inhibitor, we observed an overall decrease in the number of CD11c+ cells in the 
draining lymph node. Reduction in IL-12p40-producing cells may be partially explained by 
the overall decrease in CD11c+ cells in the draining lymph node. The observed decrease in 
these cells may point to not-accounted-for side effects of systemic ERK1/2 inhibition, 
including diminished cell survival, as ERK1/2 has been demonstrated to play a critical role in 
DC survival (34). Together these data point to an important role for ERK1/2 activation during 
the modulation of DC maturation mediated by L. amazonensis amastigotes. However, given 
the ubiquitous nature of this pathway, the data also point to the need for targeted versus 
systemic ERK inhibition as a potential anti-leishmania therapy.  
Based on the finding that L. amazonensis promastigote infection resulted in delayed 
phosphorylation of ERK1/2 as compared to amastigote infection, we explored the dynamics 
and potential mechanism of intracellular ERK1/2 activation. The delayed response in 
ERK1/2 activation could be explained by two mechanisms, requirement for a stage-specific 
ligand and/or specific signaling mediators (e.i. scaffold proteins). Since L. amazonensis 
amastigote infection leads to rapid ERK1/2 phosphorylation is it possible that an amastigote-
specific ligand (membrane-bound or secreted) is necessary to trigger this pathway. The 
variety and complexity of glycoproteins and glycolipids coating the surface of promastigotes 
and amastigotes are very different in these two stages, supporting the idea of a ligand 
requirement. We would hypothesize that our observed delayed ERK1/2 phosphorylation 
following promastigote infection is dependent on the generation of an amastigote-derived 
molecule that is expressed and/or secreted once the promastigote beings its transformation 
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into an amastigote. Moreover, the appearance of the ligand may not be sufficient to trigger 
ERK1/2 activation from endosomal compartments. Along with a specific ligand, it is possible 
that recruitment of specific signaling mediators is necessary to trigger promastigote-
mediated ERK1/2 activation.  We would suggest that promastigote internalization recruits 
signaling mediators, specifically scaffold proteins, to the parasitophorous vacuole (PV) that 
can then mediate activation of the MAPK ERK signaling cascade.  
Based on previous work which indicated that internalized growth factor receptors 
could continue to signal via the ERK1/2 pathway from late endosomal compartments 
(reviewed in (9, 38)), we hypothesized a similar mechanism of endosomal ERK1/2 activation 
could be occurring during L. amazonensis promastigote infection. Late endosomal-mediated 
activation of ERK1/2 has been shown to be facilitated by scaffold proteins, specifically MP1 
and MORG1.  
Immunofluorescence analysis of endosomal L. amazonensis-mediated ERK1/2 
phosphorylation revealed intracellular phospho-ERK1/2 co-localizing with internalized 
parasites. This data suggested that activation of this kinase from the same location as 
parasite-containing organelles. In addition, we observed co-localization of both MP1 and 
MORG1 with internalized L. amazonensis. Altogether, the data suggest a model (Figure 2) 
of L. amazonensis-mediated ERK1/2 activation from intracellular compartments facilitated by 
scaffold proteins MP1 and MORG1. Following parasite phagocytosis at the plasma 
membrane specific receptors may be triggered leading to the subsequent recruitment of 
scaffold proteins. The parasite-containing early endosome—or parasitophorous vacuole 
(PV)—proceeds through its maturation process becoming a late phagosome and eventually 
fusing with lysosomes to become a phagolysosome. Once at the late 
phagosome/phagolysosome stage, specific scaffold proteins associate with these 
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organelles, serving as platforms for the ERK signaling pathway. We know from our own 
work that activation of ERK does occur during L. amazonensis infection, leading to the 
modulation of CD40 surface expression and IL-12p40 production.  
Leishmania parasites have been shown to alter host-cell signaling pathways to 
promote their survival. Most studies aimed at understanding the regulation of signaling 
pathways triggered by Leishmania parasites have focused on the initial events of host-
parasite interactions. However, Leishmania parasites reside intracellularly within 
parasitophorous vacuoles (PV) and it is from within these intracellular compartments that 
parasites continue to engage cell signaling pathways and alter the host’s biological 
responses (18). This has been demonstrated by the presence of products of the 
phosphoinositide 3-kinase (PI3K) pathway on PV following L. amazonensis infection (35).  
PV are highly dynamic in their structure and composition. Acquisition of endosomal 
components—and their content—is an ongoing process, as fusion of newly internalized 
materials and recycled cytoplasmic molecules are delivered into lysosomal compartments, 
including Leishmania-containing PV (6). Leishmania parasites acquire many of their 
nutrients from the host cell via the host cell’s endocytic network.  Based on recent work 
suggesting the important role of endocytosis in signal transduction (reviewed in (38)), 
signaling components (i.e. extracellular receptors, lipids, kinases, adaptor and scaffold 
proteins) could be delivered to parasite-containing PV giving the parasite access to the 
host’s signaling networks.  
The model presented here provides for the first time a description of a pathogen-
mediated mechanism utilizing host-derived molecules that trigger signaling pathways 
intracellularly. The co-localization of phosphorylated ERK1/2 and the scaffold proteins MP1 
and MORG1 suggest that such a mechanism may be at work in our model of L. 
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amazonensis infection. It remains to be determined if a specific receptor/ligand interaction is 
necessary to trigger ERK1/2 activation. It is also possible that parasite-induced changes in 
the PV membrane alone may be sufficient trigger the ERK pathway once its components are 
bound to recruited scaffold proteins. In addition, the dynamic nature of PV and their steady 
acquisition of endosomal components may provide a constant source signaling components, 
which can be directly used by the parasite.  
The requirement for MP1 and/or MORG1 to facilitate ERK1/2 activation following L. 
amazonensis infection remains to be determined. However, if such a mechanism is being 
utilized by L. amazonensis, targeting of these scaffold proteins (upregulation or 
downregulation) may enable direct and specific modulation of ERK1/2 activation. 
Therapeutically, this can lead to very specialized, effective treatment options where 
regulation of ERK1/2 signaling occurs only during parasite-induced pathological cascade 
activation, without affecting steady-state ERK1/2 function. 
 
Recommendations for future studies 
 One of the future goals of the research presented in this dissertation is to understand 
how a non-productive immune response evolves during L. infantum infection. Additional 
experiments are necessary to demonstrate the mechanisms behind increased production of 
IL-10, antigen-specific antibodies and antigen load during disease progression. While it is 
evident that changes in these parameters are indicators of clinical disease, the causal 
relationship between them remains poorly understood. Characterization of the CD4+ T cell 
response to antigen from subclinical and clinical dogs should be more closely analyzed. We 
have proposed that T cell exhaustion and/or adaptive tolerance mechanisms may be at play 
during the immune response to L. infantum. It would be interesting to characterize whether 
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the disease-associated immuno-suppressed immune response results from initially-activated 
T cells that become exhausted or tolerant, or from newly-activated naïve T cells that are 
primed later in disease. CD4+ T cell subpopulations should be characterized based on 
activation/effector marker expression (CD25, CD69, CD44, CD62L), markers associated 
with adaptive tolerance (PD-1, OX40), and effector function (IFN-γ, IL-10, TGF-β). 
Additionally, in vitro studies to determine if IL-10 production is responsible for the observed 
decrease in lymphoproliferation and IFN-γ production are also warranted. The marked 
increase in antigen-specific antibody production is another point of interest that requires 
further study. It is likely that protective antibodies are found at early stages of infection but 
produced at low levels, below the detection limit of current assays. Western blot analysis of 
serum hybridization onto SDS-PAGE-electrophoresed L. infantum antigen may provide a 
more sensitive method of characterizing antigen-specific antibodies in subclinical animals.  
 The murine cutaneous leishmaniasis model also used in this dissertation has allowed 
for a closer dissection of the mechanisms leading to immune dysregulation during infection 
with another Leishmania parasite, L. amazonensis. The work presented here describes a 
molecular mechanism by which L. amazonensis modulates DC maturation phenotype by 
targeting a host signaling pathway and potentially utilizing host cell signaling components to 
do this. Additional experiments are needed to further characterize the involvement of 
scaffold proteins during L. amazonensis infection. In order to achieve this, a new cell 
system, where genetic manipulation is more readily available, is warranted. Initial studies 
should focus on cloning of tagged (i.e. FLAG, GFP) MP1 and MORG1 to facilitate co-
immunoprecipitation studies to validate the immunofluorescence studies. Continuing studies 
should also determine the requirement for MP1 and/or MORG1 during ERK1/2 
phosphorylation. Silencing inhibitory (si) RNA technology is available for both MP1 and 
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MORG1, and would be recommended for these studies. Western blot analysis can then be 
used to determine ERK1/2 phosphorylation in the absence of these proteins following L. 
amazonensis infection.  
By better understanding how the immune-dysregulation observed during L. infantum 
and L. amazonensis infection, we may be better able to develop therapeutic strategies to aid 
the immune system in fighting infection, not only against these parasites, but other chronic 
infectious disease with similar immune-regulatory patterns. 
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Figure 1. Different Leishmania diagnostics are more or less effective because of 
alterations in parasite load and immune response. Because of cost and materials 
required, serology is the most common means of diagnosing Leishmania infection, both in 
the United States and elsewhere. The antibody response measured by serology can be 
against the whole parasite, for example the CDC IFA assay (CDC, light blue bar) or to a 
specific antigen, for example the Cornell-developed kELISA (kELISA, dark blue bar). This 
difference, whole parasite response versus specific antigen, in this case may lead to 
different sensitivity and specificity to detecting infection. Whole parasite-based serology can 
also cross-react with antibodies to Trypanosoma cruzi, for instance. kELISA has been 
shown to identify infection earlier, as portrayed by the x-axis, and may detect a different 
subset of antibodies (nonproductive and productive antibodies are portrayed by the bottom 2 
sets of dashed lines). T-cell–based responses, for instance T-cell proliferation to parasite 
antigen (TCP, tan bar), detects infection very early after infection and is able to consistently 
indicate infection throughout the course of infection until very late in disease when the T-cell 
response wanes (small dashed line). Unfortunately, this assay is currently only performed on 
an experimental basis because of the time and materials required for successful analysis of 
this cellular response. Measurement of actual parasites in the bloodstream (solid line) via 
detection of parasite kinetoplast DNA via qPCR (PCR, orange bar) is another highly 
sensitive means of diagnosing parasite infection. This assay requires very rigid quality 
control to assure accurate results and, because of the nature of the test, can lead to 
occasional false-positive results. Figure and legend reprinted with permission from Elsevier 
Limited: Topics in Companion Animal Medicine, Vol. 24(4), Petersen, C.A., Leishmaniasis, 
an Emerging Disease Found in Companion Animals in the United States, pp.182-188, 
Copyright Elsevier, 2009. 
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Figure 2. Proposed model for endosomal ERK activation following Leishmania 
amazonensis infection. L. amazonensis promastigotes are phagocytosed by dendritic cells 
and (A) may initially signal through different receptor types which influence the formation of 
unique signaling scaffolds for the mitogen-activated protein kinase, ERK. (B) Parasite-
containing phagosomes proceed through the endosomal maturation process becoming late 
endosomes/lysosomes. (C) L. amazonensis-containing late endosomes recruit the p14-
MP1-MORG1 scaffolding complex. L. amazonensis infection of dendritic cells, using a 
MORG1 signaling scaffold leads to ERK phosphorylation and nuclear translocation of 
activated ERK. MORG1 signaling scaffold leads to ERK phosphorylation and nuclear 
translocation of activated ERK. 
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